Patent Publication Number: US-2022226457-A1

Title: Method for the expansion of hpv immunogen specific t-cells

Description:
FIELD OF THE INVENTION 
     The present invention relates to a method of providing therapeutically useful T-cells and their use in the treatment or prevention of cancer, particularly HPV positive cancers. 
     BACKGROUND 
     Human papillomavirus (HPV) is a DNA virus belonging to the papillomavirus family that has the capability to infect humans. HPV infection accounts for 5.2% of all cancers such as cervical cancer, oropharyngeal cancer and penile cancer, worldwide (Rubin et al., Am J Pathol. 2001, 159, 1211-1218). More than 170 HPV types have been identified (Chouhy D et al., J Gen Virol, 2013, 94, 2480-2488). Based on their risk of inducing malignancy, HPV types are grouped into high or low-risk types. The high-risk group (including HPV-8, -16, -18 and -31) are associated with cancers (Motoyama et al., Kobe J Med Sci, 2004, 50, 9-19), whereas the low-risk types (including HPV-6, and -11) can lead to benign warts and lesions without transformation. Studies on penile cancer have demonstrated that the most prevalent strain is HPV16 (Tornesello et al. Int J Cancer, 2008, 122, 132-137). Some types generally classified as ‘low risk’ can however, in some settings constitute higher risk infections. For example, a case report with invasive verrucous carcinoma of the penis reported association with the low risk HPV 11 (Dianzani et al., Urology, 1998, 51, 1046-1048). 
     The HPV genome encodes two shell proteins (L1 and L2) and six early proteins (E1, E2 and E4-E7), which support replication of the viral DNA and production of virus particles and their assembly in the infected cells (Munoz et al., Vaccine, 2006, 24 Suppl 3:S3/1-10). 
     Animal studies suggest the HPV proteins E6 and E7 could affect cell growth control by inactivating the tumour suppressors p53 and retinoblastoma protein (pRb), respectively (Pan et al., Genes Dev, 1994, 8, 1285-1299). 
     Despite the interest in immunotherapies for treating cancers, such as HPV positive cancers, they have to date had limited success. This is due to ineffective modulation or induction of a specific immune response, together with challenges associated with the safety and selectivity of the immunotherapy. 
     There are various approaches for modulating the immune system of a subject to treat cancer; such approaches are often referred to as “immunotherapies”. Examples of immunotherapies include immune checkpoint inhibitors, adoptive cell transfer (ACT) therapies, and cancer vaccines. 
     There has been much success in using immune checkpoint inhibitors for treating cancer, such as the use of monoclonal antibodies that target binding interactions that are important to checkpoints of immune activation. Immune checkpoint inhibitors have been used for the treatment of various cancers, for example in the treatment of melanoma, lung cancer, bladder cancer and gastrointestinal cancers. 
     There has also been some success with adoptive cell transfer (ACT). For example, a study in which patients with advanced colon cancer were treated using an adoptive immunotherapy protocol was reported by Karlsson et al., (Ann Surg Oncol 2010, 17(7), 1747-57). The treatment was based on the isolation and in vitro expansion of autologous tumour-reactive lymphocytes isolated intraoperatively from the first lymph node that naturally drains the tumour (the sentinel node). Sentinel node acquired lymphocytes were collected, activated, expanded against an autologous tumour extract and returned to the patient as a transfusion. No toxic side effects or other adverse effects were observed. Total or marked regression of the disease occurred in four patients with liver and lung metastases and twelve patients displayed partial regression or stable disease. 
     A significant limitation for ACT is the need to prepare sufficient quantities of immunogen specific T-cells, such as tumour-infiltrating lymphocytes (TILS), for administration to a subject. For example, current methods often require the use of invasive surgical procedures to remove a cancer or cancer cells of a subject in order to obtain antigen specific T-cells. Furthermore, the cells obtained are few and are frequently unresponsive (anergic) due to immunosuppressive mechanisms from the cancer. This can lead to in vitro expansion being slow, which in turn means that it can take a long time to obtain sufficient quantities of antigen specific T cells for therapeutic use. 
     Genetically engineered T-cells have been developed to overcome some of the limitations of ACT. Genetically engineered T-cells may be obtained by genetically redirecting a T-cell specificity towards a patient&#39;s cancer by introduction of antigen receptors or by introducing a synthetic recognition structure termed a “chimeric antigen receptor” into a T-cell. Although genetically engineered T-cells have found success in treating hematologic cancers, the safety and selectivity of genetically engineered T-cells for treating solid cancers still requires improvement. 
     There have been reports of some exploratory studies on immunotherapy for HPV-induced cancers. For example, Borysiewicz L K, et al., (Lancet, 1996, 347, 1523-1527) reported on a study in which patients were vaccinated with a single dose of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 (TA-HPV). Each patient mounted an anti-vaccinia antibody response and three of the eight patients developed a HPV-specific antibody response that could be ascribed to the vaccination. HPV-specific cytotoxic T lymphocytes were detected in one of three evaluable patients. Bagarazzi et al. reported on a study of the immune relevance of the E6 and E7 proteins in HPV associated immunotherapy of cervical cancer (Bagarazzi et al. Sci Transl Med, 2012, 4, 155-138): when subjects previously treated for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) received a three-dose (intramuscular) regimen of engineered plasmid DNA encoding HPV16 and HPV18 E6/E7, flow cytometric analysis revealed the induction of HPV-specific CD8(+) T cells that efficiently loaded granzyme B and perforin and exhibited full cytolytic functionality. 
     Bellone et al., (J Virol, 2009, 83, 6779-6789) reported a study comparing the efficiency of different HPV immunogen specific T cells in eliminating autologous HPV positive tumour cells from patients with cervical cancer. The study concludes that L1-specific CD8+ cytotoxic T cells are as effective as E7-specific CD8+ T-cells. Lastly, Stevanovic et al. (J Clin Onc, 2015, 43, 33(14):1543-1550) reported on a treatment of cervical cancer in which patients were treated with lymphocyte depleting chemotherapy followed by a single infusion of tumour-infiltrating lymphocytes. The tumour-infiltrating lymphocytes were obtained from the tumour. The lymphocytes infused were selected, where possible, for HPV E6 and E7 reactivity. Three of nine subjects experienced objective tumour responses, leading the authors to conclude that further investigations of therapies of this type are warranted. 
     Selection and expansion of the most therapeutically useful T cells is going to be central to the success of T-cell based immunotherapy of HPV-mediated cancers. There remains a need for improvements in this area to enable development of immunotherapies for use in the treatment of prophylaxis of cancers and that are also suitable for use in a clinical setting. 
     SUMMARY OF THE INVENTION 
     The present invention provides a method for the expansion of HPV immunogen specific T-cells, comprising the steps of:
     i. providing a human papillomavirus (HPV) immunogen or a phagocytosable particle comprising a core and a HPV immunogen tightly associated to the core; wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein;   ii. providing APCs   iii. contacting the HPV immunogen or the phagocytosable particle comprising a core and a HPV immunogen with the APCs from step ii in vitro, and under conditions allowing phagocytosis of the HPV immunogen by the APCs;   iv. providing T-cells that have been harvested from the subject;   v. contacting the T-cells with the APCs from step iii) in vitro, and under conditions allowing specific activation of HPV immunogen specific T-cells.   

     The present inventors have found that suitable HPV immunogens include HPV proteins necessary for viral replication (e.g. E1 to E7) and HPV coat proteins (e.g. L1 and L2). The inventors have found that HPV immunogens contained in commercially available HPV vaccine (for example Gardasil®, Gardasil 9° and/or Cervarix®) are particularly effective for use with the method of the present invention. In preferred embodiments of the invention the HPV immunogens for use in the method of the invention are one or more of HPV coat protein L1 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. 
     In certain embodiments of the invention, the HPV immunogen for use in the method of the present invention has an amino acid sequence that corresponds to a part of a HPV protein. Preferably, the HPV immunogen has an amino acid sequence that corresponds to a part of a HPV coat protein L1 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. 
     The present invention also provides a population of HPV immunogen specific T-cells for use in the treatment of a HPV positive cancer in a subject, wherein the T-cells have been prepared by a process in which T-cells are obtained from the subject, and exposed ex vivo to an HPV immunogen resulting in T-cell activation and proliferation. 
     The resulting expanded and activated T-cells are useful in the treatment of HPV positive cancers, such as HPV positive cervical, vaginal, vulval, penile, anal, mouth, throat and head and neck cancers. The expanded and activated T cells are particularly effective for the treatment of penile cancers. It has surprisingly been found by the current inventors that lymph node derived T-cells from HPV positive penile cancer patients responded in a dose dependent manner to a HPV immunogen, resulting in T-cell activation and proliferation. Furthermore, using a model virus antigen construct (CMV), the present inventors have shown that the phagocytosable particles and ex-vivo expansion method of the present invention are surprisingly effective for expanding virus-specific T-cells isolated from a subject. As such, the present inventors provide an expansion method described herein which is an effective method for preparing HPV specific T-cells, which will find utility in adoptive T-cell therapies for HPV-mediated cancers. 
     The present invention also provides a method of treating or preventing a HPV positive cancer comprising the step of administering to the subject a population of HPV immunogen specific T-cells. 
     The present invention also provides the use of a population of HPV immunogen specific T-cells for the manufacture of a medicament for the treatment or prevention of a HPV positive cancer in a subject. 
     The present invention also provides an injectable pharmaceutical composition comprising a population of HPV immunogen specific T-cells, wherein the injectable pharmaceutical composition optionally further comprises a pharmaceutically acceptable excipient and/or an adjuvant. 
     The invention also provides a phagocytosable particle comprising a core and a HPV immunogen tightly associated to the core, wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein. Such HPV proteins include, for example, HPV proteins necessary for viral replication (e.g. E1 to E7) and HPV coat proteins (e.g. L1 and L2). The present inventors have found that a particularly suitable source of HPV immunogens for use in the method of the invention is Gardasil®, Gardasil 9° and/or Cervarix®. 
     The present inventors have found that phagocytosable particles as described herein can be efficiently purified and sterilised, thus removing contaminants, such as pathogens (e.g. bacteria, fungus and viruses), endotoxins and other antigenic contaminants from the phagocytosable particles that are used in the method of the present invention. This is particularly advantageous because the removal of contaminants from the phagocytosable particles of the invention reduces contamination of the HPV specific T-cell population provided by the present invention. Reduced levels of contaminates, such as pathogens and other antigenic contaminants in the population of T-cells for administering to a subject reduces non-specific immune responses and therefore improves safety and efficacy of the HPV specific T-cell population in treating or preventing HPV positive cancers. 
     The core of a phagocytosable particle (e.g. a polymer particle) as described herein acts as a very effective carrier for the HPV immunogens. Without wishing to be bound by any particular theory, it is believed that phagocytosable particles as defined herein are especially effective because the entire phagocytosable particle, including the core and tightly associated HPV immunogen, are internalised by APCs by phagocytosis into a phagosome. The HPV immunogen is then cleaved from the core of the particle and processed in the phagosome. Fragments of the HPV immunogen are then presented on the surface of the APC via the major histocompatibility (MHC) class II pathway and presented on the cell surface by a MHC class II molecule. It is also believed that this is not the exclusive process for the HPV immunogen to be presented on surface of an APC, and that some fragments of the HPV immunogen may also be presented on the surface of APCs via the major histocompatibility (MHC) class I pathway and presented on the cell surface by a MHC class I molecule, in a process known as cross-presentation. Thus, although it is expected that fragments of the HPV immunogen are presented on APCs predominantly via the MHC class II pathway, it is expected that some will be presented via the MHC class I pathway, and so the present invention harnesses both pathways to a varying extent. 
     When antigens are presented by an MHC class II molecule, they generally activate helper T-cells (also known as CD4+ T-cells), which predominantly orchestrate immune responses by secretion of cytokines, inducing class switching of B-cells to assist the B-cells to make antibodies and stimulating activation and expansion of other T-cell types, in particular cytotoxic T-cells (e.g. CD8+ T-cells) and memory T-cells (e.g. CD8+ memory T-cells). In addition, CD4+ T-cells can directly kill other cell types (Borst et al. Nat Rev Immunol, 2018, 18(10), 635-647). This means that by administering a population of HPV immunogen specific T-cells that have been activated by the phagocytosable particles as defined herein to a subject, it is possible to administer multiple types of activated immune cells, which results in a HPV immunogen specific immune response that starts slowly (thus leading to few side effects), has a long lasting effect, and can target the cancer in many different ways by harnessing the whole immune system (rather than only activating CD8+ T-cell which can only attack the tumour cells directly). This is in contrast to what would be expected to occur when an antigen (e.g. a HPV immunogen) is provided as free peptide or a nucleotide construct that expresses the peptide. Such an antigen would be expected to be taken up into the cytosol of an APC, which results in the antigen being presented on the cell surface solely via the MHC class I pathway by an MHC class I molecule. This, in turn, results predominantly in the activation of CD8+ T-cells. Furthermore, after the administration of a first dose of antigen specific T-cells (CD4+ T-cells and CD8+ T-cells) that have been expanded ex-vivo, memory T-cells derived from the antigen specific T-cells administered to the subject remain in circulation and can mount a rapid and effective secondary immune response for as long as cancer cells expressing the HPV proteins remain in the body, or if the same cancer returns. Thus, HPV immunogen specific T-cells expanded according to the method of the present invention, when expanded and administered to a patient, will continue to work even after the original T-cells administered as a first dose to the subject have died, due to the memory T-cells that remain in circulation. 
     The present inventors also understand that it will not be necessary to remove the phagocytosable particles used in the ex-vivo expansion method of the invention from the population of T-cells before the population of T-cells are administered to a subject. Without wishing to be bound by theory, the inventors believe that this is because of the low toxicity of the core and the high sterility of the particles used in the method (for details of the sterilisation procedure see Examples 2 and 7). Not removing the phagocytosable particles from the expanded T-cells will advantageously reduce the number of steps required to prepare a population of T-cells for use in treatments according to the invention. 
    
    
     
       BRIEF DESCRIPTION OF THE FIGURES 
         FIG. 1  shows the effect of phagocytosable particle size on T-cell activation. A proliferation assay (with thymidine incorporation) was used to assess the number of splenocytes obtained from ovalbumin sensitized mice. Comparison of ovalbumin coupled to differently sized phagocytosable particle with a diameter of 5.6 μm, 1 μm and 0.2 μm are shown. P-values determined using students T-test and written indicated when p&lt;0.05 found. Staples denote SD. 
         FIG. 2A  shows the confocal microscope images of PBMCs with intracellular, phagocytosed particles. Three sizes of phagocytosable particle are shown (4.5 μm, 2.8 μm or 1 μm) following incubation for 18 h at 37° C. of PBMCs with the phagocytosed particles. 
         FIG. 2B  shows the cellular uptake of phagocytosable particles of two sizes (4.5 μm or 2.8 μm) after incubation with PBMCs for 18 h at 37° C., as assessed by manual counting. 
         FIG. 2C  shows the cellular uptake of phagocytosable particles of three sizes (4.5 μm, 2.8 μm or 1 μm) after incubation in PBMCs for 18 h at 37° C., as assessed by volume calculation (*p&lt;0.05 **p&lt;0.01 ***p&lt;0.001, calculated using Student&#39;s T-test). 
         FIG. 3A  shows the relative increase in the level of IFNγ-production in PBMCs from cytomegalovirus (CMV) sensitive healthy donors (also referred to herein as CMV positive donors), (n=2) stimulated with phagocytosable particles of three sizes (4.5 μm, 2.8 μm or 1 μm) compared to non-stimulated cells, as assessed in the FluoroSpot assay of Example 3a(iv). 
         FIG. 3B  shows the relative increase in the level of IL-22-production in PBMCs from a CMV-sensitive healthy donor (n=1) stimulated with phagocytosable particles of three sizes (4.5 μm, 2.8 μm or 1 μm) compared to non-stimulated cells, as assessed in the FluoroSpot assay of Example 3a(iv). 
         FIG. 3C  shows the relative increase in the level of IL-17-production in PBMCs from CMV-sensitive healthy donor (n=1) stimulated with phagocytosable particles of three sizes (4.5 μm, 2.8 μm or 1 μm) compared to non-stimulated cells, as assessed in the FluoroSpot assay of Example 3a(iv). 
         FIG. 3D  shows the relative increase in the dual-cytokine production of IFNγ and IL-17 in PBMCs from a CMV-sensitive healthy donor (n=1) stimulated with phagocytosable particles of three sizes (4.5 μm, 2.8 μm or 1 μm) compared to non-stimulated cells, as assessed in the FluoroSpot assay of Example 3a(iv). 
         FIG. 3E  shows the relative increase in the dual-cytokine production of IL-22 and IL-17 in PBMCs from a CMV-sensitive healthy donor (n=1) stimulated with phagocytosable particles of three sizes (4.5 μm, 2.8 μm or 1 μm) compared to non-stimulated cells, as assessed in the FluoroSpot assay of Example 3a(iv). 
         FIG. 4A  shows a correlation between CD8+ T-cells and CD56+ expressing lymphocytes in lymph nodes of the penile cancer patients in the study. 
         FIG. 4B  shows an inverse correlation between the fraction of CD19+ B cells and CD4+ T-cells in lymph nodes of the penile cancer patients in the study. 
         FIG. 4C  shows, an inverse correlation between the fraction of CD19+ B cells and the CD4+/CD8+ ratio in lymph nodes of the penile cancer patients in the study. 
         FIG. 5  shows the CD4+/CD8+ ratios in lymph nodes according to respective HPV-status of penile cancer patients in the study. 
         FIG. 6  shows the ratio of the level of blast transformation response for CD4+ and CD8+ T-cells after exposure to tumour extract from penile cancer patients in the study. 
         FIG. 7  shows the % cell blast cell response in the FASCIA assay for lymphocytes obtained PBMCs and lymph nodes of an HPV-positive penile cancer patient under various stimulation conditions. 
         FIG. 8A  shows the results of a dose response assay of blast transformation after Gardasil® was added at various levels to lymph node cell cultures from HPV positive patients. 
         FIG. 8B  shows the cell surface expression of the T-cell activation marker HLA-DR (Human Leukocyte Antigen—DR Isotype) in cell cultures after Gardasil® was added at various levels to lymph node cell cultures from HPV positive patients. 
         FIG. 9A  shows that the increase in the number of cells over 20 days in the PBMC culture after stimulation with model virus antigen particle (i.e. CMV-particles).  FIG. 9B  shows that the viability of the cells in the PBMC culture remained substantially constant over the 20 days of culturing. 
         FIG. 10A  shows the FACS gating strategy used to determine the viability and phenotype of the cells present in the PBMC culture after stimulation with the CMV-particles.  FIG. 10B  shows the percentage of cells in the PBMC culture that are CD3+ cells at Day 0 and Day 19.  FIGS. 10C and 10D  show the proportion of the cells in the PBMC culture that are CD4+, CD8+ cells, CD4+/CD8+ cells (Double Positive cells—DP) or CD4−/CD8− (Double Negative cells—DN) at Day 0 (CD4 CD8 baseline) and Day 19 (CD4 CD8 d19), respectively. 
         FIG. 11A  shows a fluorescent read of a FluoroSpot assay plate containing PBMCs that have not undergone ex-vivo expansion using the CMV-particles (referred to herein as “PBMC baseline”) and PBMCs from a culture that has been expanded using the CMV-particles (referred to as “Expanded PBMCs”). Both the PBMC baseline and the Expanded PBMCs were exposed to uncoupled beads, fresh media, albumin-binding domain (ABD), or CMV-particles prior to analysis of IFNγ release using the FluoroSpot assay. Wells containing cells that released high levels of IFN-γ displayed a higher level of fluorescence. As a control, a fluorescently tagged anti-CD3 antibody was used (first column, a-CD3).  FIG. 11B  shows a graphical representation of the fluorescence/IFNγ release shown in  FIG. 11A . 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     HPV Immunogens and HPV Immunogen Compositions 
     HPV immunogens for use in the method of the invention may preferably be selected from the HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2. 
     There are over 170 types of HPV virus. Certain HPV types are known to cause cancer in an infected individual, other HPV types are suspected of causing cancers and other types are not associated with cancer. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are considered carcinogenic, and types 26, 53, and 66 are considered as probably carcinogenic (Munoz et al., N Engl J Med 2003, 348, 518-527). Thus, in preferred embodiments of the invention, the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein derived from HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82, 26, 53 or 66. For example, the HPV immunogen may have an amino acid sequence that corresponds to the amino acid sequence of a HPV protein selected from HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived for any one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82, 26, 53 or 66. More preferably, the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein derived from any one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 or 82. More preferably, a HPV protein is derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. For example, the HPV immunogen may have an amino acid sequence that corresponds to the amino acid sequence of a HPV protein selected from one of HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived for any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. More preferably, the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV coat protein (e.g. L1 and L2) derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. Even more preferably, the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV coat protein L1 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. 
     In each case, the HPV immunogen may be a protein or peptide having an amino acid sequence corresponding to a part of the amino acid sequence of a HPV protein. The part should have a length sufficient to be able to bring about a specific immune response. For example, the part has a length of at least 10 amino acids. For example, it is at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45 or at least 50 amino acids long. The part may optionally have a length of less than or equal to 600 amino acids. For example, it is less than or equal to 500, less than or equal to 400, less than or equal to 300, less than or equal to 200, less than or equal to 100, less than or equal to 75, less than or equal to 60 or less than or equal to 50 amino acids. For example, the part may have a length of 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 85, 90, 95, 100, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, 550 or 600 amino acids. 
     The inventors have found that HPV immunogens contained in commercially available HPV vaccines such as Gardasil®, Gardasil 9° and/or Cervarix® are particularly effective for use with the method of the present invention. Gardasil® contains HPV coat protein L1 derived from HPV types 6, 11, 16 and 18; Gardasil 9° contains HPV coat protein L1 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; and Cervarix® contains HPV coat protein L1 derived from HPV types 6 and 11. Thus, in preferred embodiments, the HPV immunogen for use in the method of the present invention is a peptide present in Gardasil®, Gardasil 9° and/or Cervarix®. Preferably, the one or more HPV immunogen are peptides present in Gardasil® and/or Gardasil 9®. In one embodiment, the one or more HPV immunogen are peptides selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5. 
     In another embodiment, the one or more HPV immunogen are peptides HPV coat protein L1, E6 or E7 derived from HPV types 6, 11, 16 and 18 selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. 
     
       
         
           
               
               
               
             
               
                   
               
               
                 SEQ ID 
                   
                   
               
               
                 NO. 
                 Description 
                 Sequence 
               
               
                   
               
             
            
               
                  1 
                 HPV coat 
                 MCLYTRVLILHYHLLPLYGPLYHPRPLPLHSILVYMVHIIICGHYIILFLRNVNVFPIFL 
               
               
                   
                 protein L1 
                 QMALWRPSDNTVYLPPPSVARVVNTDDYVTPTSIFYHAGSSRLLTVGNPYFRVPA 
               
               
                   
                 derived from 
                 GGGNKQDIPKVSAYQYRVFRVQLPDPNKFGLPDTSIYNPETQRLVWACAGVEIG 
               
               
                   
                 HPV type 18 
                 RGQPLGVGLSGHPFYNKLDDTESSHAATSNVSEDVRDNVSVDYKQTQLCILGCA 
               
               
                   
                   
                 PAIGEHWAKGTACKSRPLSQGDCPPLELKNTVLEDGDMVDTGYGAMDFSTLQD 
               
               
                   
                   
                 TKCEVPLDICQSICKYPDYLQMSADPYGDSMFFCLRREQLFARHFWNRAGTMG 
               
               
                   
                   
                 DTVPQSLYIKGTGMPASPGSCVYSPSPSGSIVTSDSQLFNKPYWLHKAQGHNNG 
               
               
                   
                   
                 VCWHNQLFVTVVDTTPSTNLTICASTQSPVPGQYDATKFKQYSRHVEEYDLQFIF 
               
               
                   
                   
                 QLCTITLTADVMSYIHSMNSSILEDWNFGVPPPPTTSLVDTYRFVQSVAITCQKDA 
               
               
                   
                   
                 APAENKDPYDKLKFWNVDLKEKFSLDLDQYPLGRKFLVQAGLRRKPTIGPRKRSA 
               
               
                   
                   
                 PSATTSSKPAKRVRVRARK 
               
               
                   
               
               
                  2 
                 HPV coat 
                 MSLWLPSEATVYLPPVPVSKVVSTDEYVARTNIYYHAGTSRLLAVGHPYFPIKKPN 
               
               
                   
                 protein L1 
                 NNKILVPKVSGLQYRVFRIHLPDPNKFGFPDTSFYNPDTQRLVWACVGVEVGRG 
               
               
                   
                 derived from 
                 QPLGVGISGHPLLNKLDDTENASAYAANAGVDNRECISMDYKQTQLCLIGCKPPI 
               
               
                   
                 HPV type 16 
                 GEHWGKGSPCTNVAVNPGDCPPLELINTVIQDGDMVDTGFGAMDFTTLQANK 
               
               
                   
                   
                 SEVPLDICTSICKYPDYIKMVSEPYGDSLFFYLRREQMFVRHLFNRAGAVGENVPD 
               
               
                   
                   
                 DLYIKGSGSTANLASSNYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNNGICWG 
               
               
                   
                   
                 NQLFVTVVDTTRSTNMSLCAAISTSETTYKNTNFKEYLRHGEEYDLQFIFQLCKITL 
               
               
                   
                   
                 TADVMTYIHSMNSTILEDWNFGLQPPPGGTLEDTYRFVTSQAIACQKHTPPAPK 
               
               
                   
                   
                 EDPLKKYTFWEVNLKEKFSADLDQFPLGRKFLLQAGLKAKPKFTLGKRKATPTTSS 
               
               
                   
                   
                 TSTTAKRKKRKL 
               
               
                   
               
               
                  3 
                 HPV coat 
                 MWRPSDSTVYVPPPNPVSKVVATDAYVKRTNIFYHASSSRLLAVGHPYYSIKKVN 
               
               
                   
                 protein L1 
                 KTVVPKVSGYQYRVFKVVLPDPNKFALPDSSLFDPTTQRLVWACTGLEVGRGQPL 
               
               
                   
                 derived from 
                 GVGVSGHPLLNKYDDVENSGGYGGNPGQDNRVNVGMDYKQTQLCMVGCAPP 
               
               
                   
                 HPV type 11 
                 LGEHWGKGTQCSNTSVQNGDCPPLELITSVIQDGDMVDTGFGAMNFADLQTN 
               
               
                   
                   
                 KSDVPLDICGTVCKYPDYLQMAADPYGDRLFFYLRKEQMFARHFFNRAGTVGEP 
               
               
                   
                   
                 VPDDLLVKGGNNRSSVASSIYVHTPSGSLVSSEAQLFNKPYWLQKAQGHNNGIC 
               
               
                   
                   
                 WGNHLFVTVVDTTRSTNMTLCASVSKSATYTNSDYKEYMRHVEEFDLQFIFQLCS 
               
               
                   
                   
                 ITLSAEVMAYIHTMNPSVLEDWNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEK 
               
               
                   
                   
                 EKQDPYKDMSFWEVNLKEKFSSELDQFPLGRKFLLQSGYRGRTSARTGIKRPAVS 
               
               
                   
                   
                 KPSTAPKRKRTKTKK 
               
               
                   
               
               
                  4 
                 HPV coat 
                 MWRPSDSTVYVPPPNPVSKVVATDAYVTRTNIFYHASSSRLLAVGHPYFSIKRAN 
               
               
                   
                 protein L1 
                 KTVVPKVSGYQYRVFKVVLPDPNKFALPDSSLFDPTTQRLVWACTGLEVGRGQPL 
               
               
                   
                 derived from 
                 GVGVSGHPFLNKYDDVENSGSGGNPGQDNRVNVGMDYKQTQLCMVGCAPPL 
               
               
                   
                 HPV type 6A 
                 GEHWGKGKQCTNTPVQAGDCPPLELITSVIQDGDMVDTGFGAMNFADLQTNK 
               
               
                   
                   
                 SDVPIDICGTTCKYPDYLQMAADPYGDRLFFFLRKEQMFARHFFNRAGEVGEPVP 
               
               
                   
                   
                 DTLIIKGSGNRTSVGSSIYVNTPSGSLVSSEAQLFNKPYWLQKAQGHNNGICWGN 
               
               
                   
                   
                 QLFVTVVDTTRSTNMTLCASVTTSSTYTNSDYKEYMRHVEEYDLQFIFQLCSITLSA 
               
               
                   
                   
                 EVMAYIHTMNPSVLEDWNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKPD 
               
               
                   
                   
                 PYKNLSFWEVNLKEKFSSELDQYPLGRKFLLQSGYRGRSSIRTGVKRPAVSKASAA 
               
               
                   
                   
                 PKRKRAKTKR 
               
               
                   
               
               
                  5 
                 HPV coat 
                 MWRPSDSTVYVPPPNPVSKVVATDAYVTRTNIFYHASSSRLLAVGHPYFSIKRAN 
               
               
                   
                 protein E6 
                 KTVVPKVSGYQYRVFKVVLPDPNKFALPDSSLFDPTTQRLVWACTGLEVGRGQPL 
               
               
                   
                 derived from 
                 GVGVSGHPFLNKYDDVENSGSGGNPGQDNRVNVGMDYKQTQLCMVGCAPPL 
               
               
                   
                 HPV type 68 
                 GEHWGKGKQCTNTPVQAGDCPPLELITSVIQDGDMVDTGFGAMNFADLQTNK 
               
               
                   
                   
                 SDVPIDICGTTCKYPDYLQMAADPYGDRLFFFLRKEQMFARHFFNRAGEVGEPVP 
               
               
                   
                   
                 DTLIIKGSGNRTSVGSSIYVNTPSGSLVSSEAQLFNKPYWLQKAQGHNNGICWGN 
               
               
                   
                   
                 QLFVTVVDTTRSTNMTLCASVTTSSTYTNSDYKEYMRHVEEYDLQFIFQLCSITLSA 
               
               
                   
                   
                 EVMAYIHTMNPSVLEDWNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKPD 
               
               
                   
                   
                 PYKNLSFWEVNLKEKFSSELDQYPLGRKFLLQSGYRGRSSIRTGVKRPAVSKASAA 
               
               
                   
                   
                 PKRKRAKTKR 
               
               
                   
               
               
                  6 
                 HPV viral 
                 MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYRD 
               
               
                   
                 replication 
                 SIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNPAE 
               
               
                   
                 protein L1 
                 KLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV 
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 18 
                   
               
               
                   
               
               
                  7 
                 HPV viral 
                 MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFR 
               
               
                   
                 replication 
                 DLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINC 
               
               
                   
                 protein E6 
                 QKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL 
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 16 
                   
               
               
                   
               
               
                  8 
                 HPV viral 
                 MESKDASTSATSIDQLCKTFNLSLHTLQIQCVFCRNALTTAEIYAYAYKNLKVVWR 
               
               
                   
                 replication 
                 DNFPFAACACCLELQGKINQYRHFNYAAYAPTVEEETNEDILKVLIRCYLCHKPLCE 
               
               
                   
                 protein E6 
                 IEKLKHILGKARFIKLNNQWKGRCLHCWTTCMEDLLP 
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 11 
                   
               
               
                   
               
               
                  9 
                 HPV viral 
                 MESANASTSATTIDQLCKTFNLSMHTLQINCVFCKNALTTAEIYSYAYKQLKVLFR 
               
               
                   
                 replication 
                 GGYPYAACACCLEFHGKINQYRHFDYAGYATTVEEETKQDILDVLIRCYLCHKPLC 
               
               
                   
                 protein E6 
                 EVEKVKHILTKARFIKLNCTWKGRCLHCWTTCMEDMLP 
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 6A 
                   
               
               
                   
               
               
                 10 
                 HPV viral 
                 MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAE 
               
               
                   
                 replication 
                 PQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWCASQQ 
               
               
                   
                 protein E7 
                   
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 18 
                   
               
               
                   
               
               
                 11 
                 HPV viral 
                 MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNI 
               
               
                   
                 replication 
                 VTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP 
               
               
                   
                 protein E7 
                   
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 16 
                   
               
               
                   
               
               
                 12 
                 HPV viral 
                 MHGRLVTLKDIVLDLQPPDPVGLHCYEQLEDSSEDEVDKVDKQDAQPLTQHYQI 
               
               
                   
                 replication 
                 LTCCCGCDSNVRLVVECTDGDIRQLQDLLLGTLNIVCPICAPKP 
               
               
                   
                 protein E7 
                   
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 11 
                   
               
               
                   
               
               
                 13 
                 HPV viral 
                 MHGRHVTLKDIVLDLQPPDPVGLHCYEQLVDSSEDEVDEVDGQDSQPLKQHFQI 
               
               
                   
                 replication 
                 VTCCCGCDSNVRLVVQCTETDIREVQQLLLGTLDIVCPICAPKT 
               
               
                   
                 protein E7 
                   
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 6A 
                   
               
               
                   
               
               
                 14 
                 HPV viral 
                 MHGRHVTLKDIVLDLQPPDPVGLHCYEQLVDSSEDEVDEVDGQDSQPLKQHFQI 
               
               
                   
                 replication 
                 VTCCCGCDSNVRLVVQCTETDIREVQQLLLGTLNIVCPICAPKT 
               
               
                   
                 protein E7 
                   
               
               
                   
                 derived from 
                   
               
               
                   
                 HPV type 68 
               
               
                   
               
            
           
         
       
     
     The HPV immunogen for use in the present invention can be prepared recombinantly (for example, in  E. coli , mammalian cells or insect cells), synthetically (for example, using standard organic chemistry techniques, such as solution or solid phase peptide synthesis), or they may be prepared from polypeptides isolated from a native protein or peptide derived from an animal source, for example a human HPV positive tissue. Preferably, HPV immunogens for use in the present invention are prepared recombinantly (for example, in  E. coli , mammalian cells or insect cells). More preferably, HPV immunogen for use in the present invention is prepared recombinantly in  E. coli.    
     In one embodiment of the invention, the HPV immunogen for use in the present invention is in the form of a HPV immunogen composition comprising one or more HPV immunogens. For the avoidance of doubt, the one or more HPV immunogens present in a HPV immunogen composition as described herein may independently have any of the properties and/or characteristics of the HPV immunogens described herein. 
     HPV immunogens that have different amino acids sequences are referred to herein as the “different kinds”. HPV immunogen kinds may be different because they have amino acid sequences that correspond to different HPV proteins or they have amino acid sequences that correspond to a part of a different HPV protein, or they have amino acid sequences that correspond to a different part of the same HPV protein. HPV immunogens that have the same amino acid sequence are referred to herein as the “same kind”. Thus, in preferred embodiments of the invention, a HPV immunogen composition for use in the present invention comprises two or more different kinds of HPV immunogen (for example two or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more different kinds of HPV immunogen). In another embodiment of the invention, a HPV immunogen composition comprises more than 10 different kinds of HPV immunogen (for example 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 different kinds of HPV immunogen). For example, such a HPV immunogen composition may comprise 2 to 10 different kinds of HPV immunogens (for example 2, 3, 4, 5, 6, 7, 8, 9 or 10). Preferably, such a HPV immunogen composition may comprises 2 to 9 different kinds of HPV immunogen (for example 2, 3, 4, 6, 7, 8 or 9). 
     HPV immunogen kinds that are different because they have amino acid sequences that correspond to different HPV proteins, or parts of different HPV proteins, may be different because they correspond to a HPV viral replication protein E (for example E1, E2, E3, E4, E5, E6 or E7) or a HPV coat protein L (for example, L1 or L2)) and/or may be different because they correspond to HPV proteins of different HPV types (for example HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82, 26, 53 or 66, such as HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58). 
     In a preferred embodiment of the invention, the HPV immunogen composition comprises 9 different kinds of HPV immunogen. More preferably, the HPV immunogen composition comprises 9 different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. In another preferred embodiment of the invention, the HPV immunogen composition comprises 4 different kinds of HPV immunogen. More preferably, the HPV immunogen composition comprises 4 different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from a different one of HPV types 6, 11, 16 and 18. In another preferred embodiment of the invention, the HPV immunogen composition comprises 2 different kinds of HPV immunogen. More preferably, the HPV immunogen composition comprises 2 different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from a different one of HPV types 6 and 11. 
     In another embodiment of the invention, the HPV immunogen composition comprises at least 2 different kinds of immunogen. More preferably, the HPV immunogen composition comprises at least 2 different kinds of HPV immunogen wherein at least one amino acid sequence corresponds to the amino acid sequence of a HPV coat protein L (for example, a HPV coat protein L1 or L2, and in particular a HPV coat protein L1, for example derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58) and at least one amino acid sequence corresponds to the amino acid sequence of a HPV viral replication protein E (for example, a HPV viral replication protein E1, E2, E3, E4, E5, E6 or E7, in particular E6 or E7, for example derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58). 
     In another embodiment of the invention, the HPV immunogen composition comprises at least 2 different kinds of immunogen. More preferably, the HPV immunogen composition comprises at least 2 different kinds of HPV immunogen corresponding to a HPV viral replication protein E (for example, a HPV viral replication protein E1, E2, E3, E4, E5, E6 or E7, in particular E6 or E7, for example derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58). For example, wherein at least one amino acid sequence corresponds to the amino acid sequence of a HPV viral replication protein E6 (in particular a HPV viral replication protein E6 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58), and at least one amino acid sequence corresponds to the amino acid sequence of a HPV viral replication protein E7 (in particular a HPV viral replication protein E7 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58). 
     In another embodiment of the invention, the HPV immunogen composition comprises at least 3 different kinds of immunogen. More preferably, the HPV immunogen composition comprises at least 3 different kinds of HPV immunogen wherein at least one amino acid sequence corresponds to the amino acid sequence of a HPV coat protein L1 (in particular a HPV coat protein L1 or L2, and in particular a HPV coat protein L1, for example derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58), at least one amino acid sequence corresponds to the amino acid sequence of a HPV viral replication protein E6 (in particular a HPV viral replication protein E6 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58), and at least one amino acid sequence corresponds to the amino acid sequence of a HPV viral replication protein E7 (in particular a HPV viral replication protein E7 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58). 
     In certain embodiments, the HPV immunogen composition comprises 4 different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5. In another preferred embodiment of the invention, the HPV immunogen composition comprises 2 different kinds of HPV immunogen. More preferably, the HPV immunogen composition comprises 2 different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from a different one of SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5. 
     In each case, the HPV immunogen may be a protein or peptide having an amino acid sequence corresponding to a part of the amino acid sequence of a HPV protein. The part should have a length sufficient to be able to bring about a specific immune response. For example, the part has a length of at least 10 amino acids. For example, it is at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45 or at least 50 amino acids long. 
     Thus, in certain embodiments the HPV immunogen may be a protein or peptide having an amino acid sequence corresponding to a part of the amino acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, or SEQ ID NO. 14. The part should have a length sufficient to be able to bring about a specific immune response. For example, the part has a length of at least 10 amino acids. For example, it is at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45 or at least 50 amino acids long. 
     A HPV immunogen compositions for use in the present invention may further comprise an adjuvant. The term “adjuvant” as used herein is to be understood as any substance that enhances an immune response towards an antigen. Examples of adjuvants for use in the present invention include dsRNA analogues, such as polyinosinic:polycytidylic acid, Incomplete Freund&#39;s Adjuvant, cytokines (for example, interleukins), CD40, keyhole limpet hemocyanin, Toll-like receptors, CpG oligodeoxynucleotides, saponins, aluminium salts (for example aluminium hydroxyphosphate sulphate, or aluminium hydroxide, hydrated (Al(OH) 3 , for example with 3-O-desacyl-4′-monophosphoryl lipid A (MPL) adsorbed on its surface), colloidal alum, and analogues of lipid A of lipopolysaccharide. 
     The Phagocytosable Particle and the Core of the Phagocytosable Particle 
     A phagocytosable particle of the present invention is a particle able to be phagocytosed by cells of the immune system. It should be understood, however, that phagocytosable particles of the present invention may also be internalised by cells of the immune system via different routes (e.g. pinocytosis, clathrin-mediated endocytosis and non-clathrin-mediated endocytosis). Preferably, the phagocytosable particles are phagocytosable by an APC, for example a monocyte, dendritic cell, B-cell or macrophage, or other cells that either phagocytose or internalise extracellular molecules, such as antigens, and present antigen-derived peptides on MHC class II and/or MHC class I molecules to CD4+ T-cells and/or CD8+ T-cells. 
     Antigens that are internalised into an APC by the phagocytic route are degraded in a non-uniform manner, which subsequently leads to a wide variety of antigen-derived peptides being presented by the APC. Without wishing to be bound by theory, it is believed that the phagocytosable particles for use in the present invention bring about particularly effective activation and expansion of HPV immunogen specific T-cells because the HPV immunogen is phagocytosed by APCs, which subsequently leads to a wide variety of HPV immunogen-derived peptides being presented by the APC and thus particularly effective activation and expansion of HPV immunogen specific T-cells. 
     For a particle to be phagocytosed by a cell of the immune system, such as an APC, the particle needs to be within a size range suitable to allow for phagocytosis. For example, a particle that is too small may not trigger phagocytosis by a particular APC, or a particle that is too large may not be phagocytosable by a particular APC. Complete phagocytosis leads to good antigen degradation by APCs and subsequently good presentation to T-cells via the MHC class II pathway. The optimal size has been investigated by the current inventors (see Examples 3a and 3b, and  FIGS. 1, 2A -C, and  3 A-E). 
     A phagocytosable particle of the present invention comprises a core, and a HPV immunogen tightly associated to the core. Thus, the size of the core needs to be within a range such that when the core is tightly associated to a HPV immunogen, the core and the tightly associated HPV immunogen are phagocytosable by a cell of the immune system, and in particular an APC. It is preferred that the size of the core is within a range such that when the core is tightly associated to a HPV immunogen, the core and the tightly associated HPV immunogen are small enough that more than one phagocytosable particle can enter the same APC by phagocytosis. Having more than one phagocytosed particle in an APC maximises presentation of HPV immunogen fragments on the cell surface via the MHC class II pathway. Furthermore, it allows particles having different HPV immunogen (in particular HPV immunogens comprising different kinds of HPV immunogen) to enter an APC, which means that the APC can present different HPV immunogens from several particles in different phagosomes at the same. 
     As such, in one preferred embodiment, the core has a largest dimension of less than 6 μm, less than 5.6 μm, less than 4 μm, less than 3 μm, less than 2.5 μm, less than 2 μm or less than 1.5 μm. More preferably the core has a largest dimension of less 1.5 μm. In another preferred embodiment, the core may have a largest dimension of greater than 0.001 μm, greater than 0.005 μm, greater than 0.01 μm, greater than 0.05 μm, greater than 0.1 μm, greater than 0.2 μm or greater than 0.5 μm. More preferably the core has a largest dimension of greater than 0.5 μm. 
     In one especially preferred embodiment, the core has a largest dimension in the range of 0.1 to 6 μm, for example 0.1 to 5.6 μm, 0.2 to 5.6 μm, 0.5 to 5.6 μm, 0.1 to 4 μm or 0.5 to 4 μm. More preferably the core has a largest dimension in the range of 0.1 to 3 μm, for example, 0.5 to 3 nm, 0.2 to 2.5 nm, 0.5 to 2.5 nm, 0.2 to 2 nm, 0.5 to 2 μm or 1 to 2 nm. Even more preferably, the core has a largest dimension of about 1 μm, about 1.5 μm or about 2 μm. In a very preferred embodiment of the invention, the core is about 1 μm. 
     The core of the phagocytosable particle of the invention takes the form of any three-dimensional shape, for example any regular or irregular three-dimensional shape. Preferably, the phagocytosable particle is substantially spherical, in which case the dimensions of the phagocytosable particle refers to diameter. 
     The core of a phagocytosable particle may comprise a polymer, glass, ceramic material (e.g. the core may be a polymer particle, a glass particle or a ceramic particle). The material of the core may be a biodegradable and/or biocompatible material (e.g. the particle may be a biodegradable and/or biocompatible particle). 
     Preferably, the core comprises a polymer (for example, the core is a polymer particle). If the core comprises a polymer, it may be selected from the group consisting of a synthetic aromatic polymer (such as polystyrene e.g. the core is a polystyrene particle), a synthetic non-aromatic polymer (such as polyethylene, polylactic acid, poly(lactic-co-glycolic acid) and polycaprolactone, e.g. the core is a polyethylene particle, polylactic acid particle, poly(lactic-co-glycolic acid) particle or polycaprolactone particle), a naturally occurring polymer (such as collagen, gelatine, proteins (e.g. virus-like particles), lipids or albumin, e.g. the core is a collagen particle, gelatine particle or albumin particle), a polymeric carbohydrate molecule (such as a polysaccharide, for example agarose, alginate, chitosan or zymosan e.g. the core is an agarose particle, alginate particle, chitosan particle or zymosan particle). 
     In one preferred embodiment, the core comprises polystyrene or polyethylene, and more preferably comprises polystyrene (e.g. the core is a polystyrene particle). Such polymers are biocompatible. 
     The present inventors have found that polystyrene particles are a particularly useful core for a phagocytosable particle of the present invention because they are nontoxic and are widely commercially available in various sizes and in various functionalisable forms. Furthermore, the present inventors have found phagocytosable particles comprising a polystyrene core, such as a polystyrene particle, are able to withstand stringent sterilisation procedures to prepare the particles for administration to a subject. Such sterilisation procedures may include repeated washed with acid or alkali solutions and/or exposure to high temperatures. 
     In one very preferred embodiment of the invention, the core is a polystyrene particle with a largest dimension of less than 6 μm, preferably from about 1 μm to about 3 μm, and more preferably about 1 μm. Phagocytosable particles comprising a polystyrene particle core with a dimension of about 1 μm to about 3 μm, and especially about 1 μm, are efficiently phagocytosed by APCs and are also able to withstand stringent sterilisation procedures to remove pathogens (e.g. bacteria, fungus and viruses) and antigenic contaminants, such as pyrogens (e.g. endotoxins), which may be associated to the core or HPV immunogen. 
     In one embodiment of the invention, the core has magnetic properties. For example, the core may have paramagnetic or superparamagnetic properties. Preferably, the core has superparamagnetic properties. 
     An example of a superparamagnetic core suitable for use with the invention are Dynabeads™ (Invitrogen). Dynabeads™ are available in various functionalisable forms, for example Dynabeads M-270 Carboxylic acid, Dynabeads M-270 Amine, and Dynabeads MyOne Carboxylic acid. Dynabeads™ are monosized superparamagnetic particles, which are composed of highly cross-linked polystyrene with evenly distributed magnetic material. The magnetic material may be iron oxide. Other examples of magnetic cores, in particular superparamagnetic cores, include Encapsulated Carboxylated Estapor® SuperParamagnetic Microspheres (Merck Chimie S.A.S.) and Sera-Mag SpeedBeads (hydrophilic) Carboxylate-Modified Magnetic particles (GE Healthcare UK Limited). Encapsulated Carboxylated Estapor® SuperParamagnetic Microspheres are made of a core-shell structure which encapsulates an iron oxide core. Preferably, the core is a Sera-Mag SpeedBeads (hydrophilic) Carboxylate-Modified Magnetic particle (GE Healthcare UK Limited). 
     A phagocytosable particle of the present invention comprises a HPV immunogen tightly associated to the core. A HPV immunogen may be tightly associated to a core using a variety of means. For example, the HPV immunogen may be attached to a core by a covalent bond, for example an amide bond between an amine group or a carboxylic acid group of the HPV immunogen and a carboxylic acid group or an amine group on the surface of the core. Alternatively, a HPV immunogen may be linked to a core via a metal chelate. For example, cores linked with a metal chelating ligand, such as iminodiacetic acid can bind metal ions such as Cu 2+ , Zn 2+ , Ca 2+ , Co 2+  or Fe 3+ . These metal chelates can in turn bind proteins and peptides containing for example histidine or cysteine with great strength. Thus, cores with metal chelates can non-covalently bind to a HPV immunogen. Preferably, the HPV immunogen is covalently attached to the core. One example of associating a polypeptide, such as a HPV immunogen, to the core is shown in Example 1. 
     A phagocytosable particle of the present invention comprises a core, and a HPV immunogen tightly associated to the core. A phagocytosable particle of the invention may comprise one or more HPV immunogens associated to the core. For example, a phagocytosable particle of the invention may comprise 1 to 3 million HPV immunogens, preferably 1 to 2 million HPV immunogens, and more preferably 1 to 1 million HPV immunogens, for example 1 to 800,000, 1 to 500,000, 1 to 100,000, 1 to 10,000, 1 to 1000, 1 to 100, or 1 to 10 HPV immunogens; or for example 10 to 1 million, 100 to 1 million, 1000 to 1 million, 10,000 to 1 million, 100,000 to 1 million, or 500,000 to 1 million. Preferably a phagocytosable particle of the invention may comprise 500,000 to 1 million HPV immunogens. 
     In preferred embodiments, to maximise the delivery of HPV immunogen into an APC (which can then be cleaved from the phagocytosable particle and processed by an APC, thus resulting in the presentation of a wide variety of HPV-derived peptides on the surface of the APCs), a phagocytosable particle of the invention may comprise more than one (i.e. two or more, for example two to 3 million) HPV immunogen associated to the core. For example, phagocytosable particle of the invention may comprise a 2 to 1 million HPV immunogens tightly associated to a core (for example 2 to 800,000, 2 to 500,000, 2 to 100,000, 2 to 10,000, 2 to 1000, 2 to 100, or 2 to 10 HPV immunogens tightly associated to a core). Preferably, a phagocytosable particle of the invention comprises 10 or more HPV immunogens tightly associated to a core, such as 10 to 1 million HPV immunogens tightly associated to a core (for example 10 to 800,000, 10 to 500,000, 10 to 100,000, 10 to 10,000, 10 to 1000, or 10 to 100 HPV immunogens tightly associated to a core). More preferably a phagocytosable particle of the invention comprises 100 or more HPV immunogens tightly associated to a core, such as 100 to 1 million HPV immunogens tightly associated to a core (for example 100 to 800,000, 100 to 500,000, 100 to 100,000, 100 to 10,000, or 100 to 1000 HPV immunogens tightly associated to a core). In certain embodiments a phagocytosable particle of the invention comprises 1000 or more HPV immunogens tightly associated to a core, such as 1000 to 1 million HPV immunogens tightly associated to a core (for example 1000 to 800,000, 1000 to 500,000, 1000 to 100,000, or 1000 to 10,000 HPV immunogens tightly associated to a core). In certain embodiments a phagocytosable particle of the invention comprises 10,000 or more HPV immunogens tightly associated to a core, such as 10,000 to 1 million HPV immunogens tightly associated to a core (for example 10,000 to 800,000, 10,000 to 500,000, or 10,000 to 100,000 HPV immunogens tightly associated to a core). In certain embodiments a phagocytosable particle of the invention comprises 100,000 or more HPV immunogens tightly associated to a core, such as 100,000 to 1 million HPV immunogens tightly associated to a core (for example 100,000 to 800,000 or 100,000 to 500,000 HPV immunogens tightly associated to a core). 
     In embodiments of the invention, where a phagocytosable particle of the invention may comprise more than one HPV immunogen associated to the core (for example 2 or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more HPV immunogens associated to the core), the HPV immunogen associated to the core may be the same kind, or may be different kinds (i.e. some or all of the HPV immunogens associated to the core may be different kinds). 
     Phagocytosable particles comprising two or more different kinds of HPV immunogens are able to deliver a wide variety of HPV immunogens into an APC and thus increase the variety of HPV-derived peptides that are presented by the APC. The present inventors have found that this significantly improves the activation and expansion of HPV immunogen specific T-cells that are able to target cancer cells. 
     A phagocytosable particle comprising more than one HPV immunogen associated to the core (for example two or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more HPV immunogens associated to the core) of the invention can comprise one kind of HPV immunogen tightly associated to a core (i.e. all the HPV immunogens tightly associated to the core are the same). In one embodiment of the invention, a phagocytosable particle comprises 100,000 to 1 million HPV immunogens tightly associated to a core, wherein the 100,000 to 1 million HPV immunogens are the same kind of HPV immunogen. Preferably, the HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of an HPV protein selected from HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived from any one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82, 26, 53 or 66. More preferably, the HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of a HPV protein selected from HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived from any one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 or 82. More preferably, the HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of a HPV protein selected from HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. For example, the HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14 or SEQ ID NO. 15. More preferably, the HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of a HPV protein selected the HPV coat protein L1 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. For example, the HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, or SEQ ID NO. 5. 
     In another embodiment of the invention, a phagocytosable particle comprising more than one HPV immunogen associated to the core (for example two or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more HPV immunogens associated to the core) can comprise two different kinds of HPV immunogen tightly associated to a core. For example, a phagocytosable particle comprising more than 10 HPV immunogens associated to the core (for example 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more HPV immunogens associated to the core) can comprise two or more different kinds of HPV immunogen tightly associated to a core. For example, such a phagocytosable particle may comprise two or more different kinds of HPV immunogen (for example two or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more different kinds of HPV immunogen). Preferably, each of the two or more different kinds of HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of a HPV protein selected from HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived from any one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82, 26, 53 or 66. More preferably, each of the two or more different kinds of HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of a HPV protein selected from HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived from any one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 or 82. More preferably, each of the two or more different kinds of HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of a HPV protein selected from HPV viral replication proteins E1, E2, E3, E4, E5, E6 and E7 and the HPV coat proteins L1 and L2 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. More preferably, each of the two or more different kinds of HPV immunogen has an amino acid sequence corresponding to the amino acid sequence of a HPV protein selected the HPV coat protein L1 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. 
     In preferred embodiments of the invention, a phagocytosable particle comprising more than one HPV immunogen associated to the core (for example two or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more HPV immunogens associated to the core) comprises 9 different kinds of HPV immunogen. More preferably, the phagocytosable particle comprises 9 different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. In another preferred embodiment of the invention, a phagocytosable particle comprising more than one HPV immunogen associated to the core (for example two or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more HPV immunogens associated to the core) comprises 4 different kinds of HPV immunogen. More preferably, the phagocytosable particle comprises 4 different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from HPV types 6, 11, 16 and 18. In another preferred embodiment of the invention, a phagocytosable particle comprising more than one HPV immunogen associated to the core (for example two or more, 10 or more, 100 or more, 1000 or more, 10,000 or more, 100,000 or more, or 500,000 or more HPV immunogens associated to the core) comprises 2 different kinds of HPV immunogen. More preferably, the phagocytosable particle comprises 2 (or 3, or 4) different kinds of HPV immunogen each having an amino acid sequence corresponding to the amino acid sequence of a HPV coat protein L1 derived from HPV types 6 and 11. 
     In each case, the HPV immunogen may be a protein or peptide having an amino acid sequence corresponding to a part of the amino acid sequence of a HPV protein (for example, corresponding to a part of the amino acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14 or SEQ ID NO. 15, and in particular a part of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or SEQ ID NO. 5). The part should have a length sufficient to be able to bring about a specific immune response. For example, the part has a length of at least 10 amino acids. For example, it is at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45 or at least 50 amino acids long. The part may optionally have a length of less than or equal to 600 amino acids. For example, it is less than or equal to 500, less than or equal to 400, less than or equal to 300, less than or equal to 200, less than or equal to 100, less than or equal to 75, less than or equal to 60 or less than or equal to 50 amino acids. For example, the part may have a length of 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 85, 90, 95, 100, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, 550 or 600 amino acids. If the phagocytosable particle comprises two different kinds of HPV immunogen tightly associated to a core, each different kind may be a protein or peptide having an amino acid sequence of the same length or an amino acid sequence of a different length. 
     The present invention also provides a phagocytosable particle composition comprising a phagocytosable particle of the invention. A phagocytosable particle composition of the invention comprising a phagocytosable particle as described herein may comprise one or more phagocytosable particles. Preferably, it comprises more than one particle. In such embodiments, the phagocytosable particles may be the same, or they may be different. Phagocytosable particles may be different due to the core and/or may be different due to comprising different types of HPV immunogens tightly associated to the core. Preferably, in a composition comprising phagocytosable particles of the invention in which the phagocytosable particles are different, the phagocytosable particles have the same core and are different due to the particles comprising different types of HPV immunogen tightly associated to the core. 
     Phagocytosable particles having different cores (e.g. cores having different sizes and/or comprising different materials/polymers as described herein) are referred to herein as phagocytosable particles of a “different set”. Phagocytosable particles having the same core (e.g. cores having the same size and comprising the same materials/polymer) may be referred to herein as phagocytosable particles of the “same set”. 
     Phagocytosable particles that have the same core (i.e. they are of the same phagocytosable particle set), but that are different due to having different kind(s) of HPV immunogen construct tightly associated to the core, are referred to herein as phagocytosable particles of “different groups”. Phagocytosable particles that have the same core and the same kind(s) of HPV immunogen tightly associated to the core are referred to herein as phagocytosable particles of the “same group”. 
     In one embodiment, a phagocytosable particle composition of the invention comprises one phagocytosable particle set which consists of one phagocytosable particle group (i.e. all of the phagocytosable particles in the composition are the same). Alternatively, a phagocytosable particle composition of the invention can comprise one phagocytosable particle set which comprises two or more different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, or more phagocytosable particle groups). In another embodiment, a phagocytosable particle composition of the invention can comprise one phagocytosable particle set which comprises 2 to 75 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75 phagocytosable particle groups). In another embodiment, a phagocytosable particle composition of the invention can comprise one phagocytosable particle set which comprises 2 to 40 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40 phagocytosable particle groups). In another embodiment, a phagocytosable particle composition of the invention can comprise one phagocytosable particle set which comprises 2 to 18 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 phagocytosable particle groups). In another embodiment, a phagocytosable particle composition of the invention can comprise one phagocytosable particle set which comprises 2 to 15 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 phagocytosable particle groups). In another embodiment, a phagocytosable particle composition of the invention can comprise one phagocytosable particle set which comprises 2 to 9 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle groups). In another embodiment, a phagocytosable particle composition of the invention can comprise one phagocytosable particle set which comprises 2 to 4 different groups of phagocytosable particle (for example 2, 3 or 4 phagocytosable particle groups). 
     In one embodiment, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (i.e. each set having different cores, for example each set having cores of different sizes and/or comprising different materials as described herein) and each set can consist of one phagocytosable particle group. For example, the phagocytosable particle composition of the invention may comprise 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets and each set can consist of one phagocytosable particle group. 
     In one embodiment of the invention, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets) and each set can comprise of two or more different phagocytosable particle group (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, or more phagocytosable particle groups). In another embodiment of the invention, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets) and each set can comprise of 2 to 75 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75 phagocytosable particle groups). In another embodiment of the invention, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets) and each set can comprise of 2 to 40 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40 phagocytosable particle groups). In another embodiment of the invention, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets) and each set can comprise of 2 to 18 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 phagocytosable particle groups). In another embodiment of the invention, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets) and each set can comprise of 2 to 15 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 phagocytosable particle groups). In another embodiment of the invention, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets) and each set can comprise of 2 to 9 different groups of phagocytosable particle (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle groups). In another embodiment of the invention, a phagocytosable particle composition of the invention can comprise two or more different phagocytosable particle sets (for example 2, 3, 4, 5, 6, 7, 8 or 9 phagocytosable particle sets) and each set can comprise of 2 to 4 different groups of phagocytosable particle (for example 2, 3 or 4 phagocytosable particle groups). 
     For the avoidance of doubt, in phagocytosable particle compositions in embodiments having more than one group of phagocytosable particle and more than one set of phagocytosable particle, each group of a phagocytosable particle set is independent from each group of another phagocytosable particle set. Thus, a group from one phagocytosable particle set can have the same kind(s) of HPV immunogen as a group from another phagocytosable particle set. Alternatively, a group from one phagocytosable particle set can have HPV immunogens that are a different kind(s) to those of a group from another phagocytosable particle set. 
     Sterilisation of the Phagocytosable Particles 
     It has been found that phagocytosable particles comprising a core and a HPV immunogen tightly associated to the core, may be efficiently washed and sterilised before administration to a subject. This is particularly advantageous because the washed and sterilised phagocytosable particles comprise lower levels pathogens (e.g. bacteria, fungus and viruses) and other antigenic contaminants such as pyrogens (e.g. endotoxins). Such contaminants can elicit non-specific immune responses in the subject. Washing and sterilising phagocytosable particles of the invention before administration to APCs (i.e. contacting the phagocytosable particles with APCs) therefore improves their safety and efficacy. 
     In one embodiment of the invention, the phagocytosable particle comprises a magnetic core, for example a paramagnetic or superparamagnetic core. A phagocytosable particle comprising a magnetic core, can be collected and/or held in place by a magnet. It is also possible to perform a wash by other means, such as by holding the phagocytosable particles (whether paramagnetic or not) in a column, or sedimenting the particles by gravity or by centrifugation. 
     The particular manner of the wash is not critical in the context of the present invention. For instance, the wash may involve subjecting a phagocytosable particle to a high pH, to a low pH, to a high temperature, to a sterilising/denaturing agent or a combination thereof. 
     The wash may involve subjecting the phagocytosable particle to alkali, preferably a strong alkali, for example at least 0.1M, 0.5M, 1M, 2M, 3M, 4M, 5M, 6M, 7M or 8M alkali. Preferably, the wash may involve subjecting the phagocytosable particle to at least 1M sodium hydroxide (NaOH), for example at least 2M NaOH. Preferably, the wash involves subjecting the phagocytosable particle to a high pH of at least 13.0, more preferably at least 14.0, most preferably at least 14.3. Other alkalis that may be used include, but are not limited to: lithium hydroxide (LiOH), potassium hydroxide, (KOH), rubidium hydroxide (RbOH), cesium hydroxide (CsOH), magnesium hydroxide (Mg(OH) 2 ), calcium hydroxide (Ca(OH) 2 ), strontium hydroxide (Sr(OH) 2 ), and barium hydroxide (Ba(OH) 2 ). Preferably, the wash involves subjecting the phagocytosable particle to a high pH of at least 13.0, more preferably at least 14.0, most preferably at least 14.3. 
     The wash may also involve subjecting the phagocytosable particle to an acid, preferably a strong acid, for example at least 0.1M, 0.5M, 1M, 2M, 3M, 4M, 5M, 6M, 7M or 8M acid. Preferably, the wash may involve subjecting the phagocytosable particle to at least 1M hydrochloric acid (HCl), for example at least 2M HCl. Other acids that may be used include, but are not limited to: hydroiodic acid (HI), hydrobromic acid (HBr), perchloric acid (HClO 4 ), nitric acid (HNO 3 ) and sulfuric acid (H 2 SO 4 ). 
     The wash may also involve subjecting the phagocytosable particle to further sterilising/denaturing agents, such as urea and/or guanidine-HCl. 
     Preferably, the wash results in the phagocytosable particle being aseptic and/or sterile. More preferably, the wash results in the phagocytosable particle being sterile. Aspetic as defined herein is being free from pathogens (i.e. disease-causing microorganisms and viruses). Sterile is defined herein as being free from all biological contaminants. Preferably, the wash also removes antigenic contaminants such as pyrogens (e.g. endotoxins) from the phagocytosable particle. Preferably, the wash provides the phagocytosable particle with an endotoxin contamination of less than 100 pg/ml, preferably less than 50 pg/ml, more preferably less than 25 pg/ml and most preferably less than 10 pg/ml. Thus, in a preferred embodiment of the invention the phagocytosable particle is sterile and has an endotoxin contamination of less than 100 pg/ml. 
     A particular advantage of the wash is that the conditions may be selected such that the phagocytosable particle is both sterilized and denatured in a single step. In particular, a high pH wash (e.g. pH &gt;14) can conveniently, simultaneously and quickly, sterilise the phagocytosable particle and eliminate a sufficient quantity of endotoxin and other antigenic contaminants. 
     The wash may comprise a single wash or several repeated washes, such as 2, 3, 4 or 5 washes. In addition, or alternatively, the phagocytosable particle may be subjected to a high temperature, such as at least 90° C., preferably at least 92° C., more preferably at least 95° C., for example at least 100° C. or at least 110° C. 
     The present inventors have advantageously found that when a HPV immunogen is associated to a core by a covalent bond, the phagocytosable particle can withstand stringent sterilisation and washing procedures that reduce the amount of pathogens (e.g. bacteria, fungus and viruses) and other antigenic contaminants such as pyrogens (e.g. endotoxins), that may be bound to a HPV immunogen or core. This means that the phagocytosable particles described herein are especially suitable for use in the present method of expanding HPV immunogen specific T-cells for use in the treatment or prophylaxis of cancer. 
     Kits of the Invention 
     The invention further provides a kit comprising phagocytosable particle of the invention and reagents suitable for use in expanding a T-cell population. The kit may further comprise reagents for assisting in expanding a T-cell population, such as IL-2. It may optionally also comprise IL-7 and/or IL-15. The kit may further comprise reagents for sterilising the phagocytosable particles of the invention. 
     The invention further provides a kit comprising a core as described herein, coupling reagents for coupling one or more HPV immunogens to the core, and reagents suitable for use in expanding a T-cell population. 
     The kit may further comprise one or more HPV immunogens or reagents for producing HPV immunogens, for example ready-to-use vectors adjusted for different cloning and expression conditions, or that comprise a cDNA sequence encoding one or more HPV immunogens. The one or more HPV immunogens in the kit may include the immunogenic peptide components of a commercially available vaccine composition, for example it may contain one or more of the components of a composition sold under the name Gardasil®, Gardasil 9° or Cervarix®. For example, in one embodiment the kit may comprise immunogenic peptide components selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. 
     Ex-Vivo Activation and Expansion of HPV Immunogen Specific T-Cells 
     The method of the invention includes the provision of APCs in step ii and T-cells in step iv. The T-cells are T-cells that have been harvested from a subject having a HPV positive cancer. The T-cell sample is therefore expected to contain T-cells that are HPV immunogen specific. They are generally present at only a low level. 
     The harvested APCs must be compatible with the HPV immunogen specific T-cells, such that they are capable of presenting antigens to the HPV immunogen specific T-cells in an antigen-specific context (MHC restricted) that the HPV immunogen specific T-cells can react to. 
     The APCs and HPV immunogen specific T-cells are preferably obtained from the same species and donor-matched with respect to MHC receptors. However, use of genetically engineered APCs from a different species is also envisioned. More preferably the APCs and HPV immunogen specific T-cells are obtained from the same subject. If the APCs and HPV immunogen specific T-cells are derived from the same subject, any potential for a mismatch between the APCs and HPV immunogen specific T-cells is avoided. 
     The APCs harvested from a subject may comprise phagocytes, monocytes and/or dendritic cells. The HPV immunogen specific T-cells may comprise CD4+ and/or CD8+ T-cells. 
     The APCs and HPV immunogen specific T-cells may be harvested from a blood sample derived from a subject. Preferably, the blood sample is a peripheral blood mononuclear cell (PBMC) sample. Obtaining PBMCs from peripheral blood samples is a routine protocol, which provides a convenient source for both APCs and T-cells at the same time and from the same subject. The PBMC sample may be freshly used or it may be subjected to freezing for storage before use. PBMCs are a fraction of human blood prepared by density gradient centrifugation of whole blood. The PBMCs mainly consists of lymphocytes (70-90%) and monocytes (10-30%), while red blood cells, granulocytes and plasma have been removed. Monocytes may in some instances make up 10 to 20% of the cell numbers in a PBMC sample, for example 10 to 15%. 
     APCs and HPV immunogen specific T-cells may also may be derived from a tumour of the subject, for example a sample derived from a lymphatic vessel in a tumour or a tumour draining lymph node (sometimes referred to as a sentinel node). Preferably, the APCs and HPV immunogen specific T-cells are harvested from a HPV positive tumour and/or a sentinel node associated with a HPV positive cancer in a subject. 
     Preferably, the APCs and HPV immunogen specific T-cells are harvested from the same sample derived from the subject and/or the same tumour of the subject. Alternatively, or additionally, APCs and HPV immunogen specific T-cells may be harvested from different samples derived from the subject. For example, the APCs may be harvested from a blood sample and the HPV immunogen specific T-cells may be harvested from a tumour and/or a sentinel node. 
     In the expansion method of the invention, the harvested APCs are contacted with a HPV immunogen (optionally tightly associated with a core as part of a phagocytosable particle). The HPV immunogen may be at a concentration of 0.01 μg/ml to 1000 μg/ml, 0.01 μg/ml to 100 μg/ml, 0.01 μg/ml to 10 μg/ml or 0.01 μg/ml to 1 μg/ml. For example, the dose may be 0.1 μg/ml to 1000 μg/ml, 0.1 μg/ml to 750 μg/ml, 0.1 μg/ml to 500 μg/ml, 0.1 μg/ml to 400 μg/ml, 0.1 μg/ml to 300 μg/ml, 0.1 μg/ml to 200 μg/ml, 0.1 μg to 100 μg, 0.1 μg to 50 μg/ml, 0.1 μg/ml to 40 μg/ml, 0.1 μg/ml to 30 μg/ml, 0.1 μg/ml to 20 μg/ml, 0.1 μg/ml to 10 μg/ml or 0.1 μg/ml to 10 μg/ml, 0.1 μg/ml to 9 μg/ml 0.1 μg/ml to 8 μg/ml 0.1 μg/ml to 7 μg/ml 0.1 μg/ml to 6 μg/ml 0.1 μg/ml to 5 μg/ml, 0.1 μg/ml to 4 μg/ml, 0.1 μg/ml to 3 μg/ml, 0.1 μg/ml to 2 μg/ml or 0.1 μg/ml to 1 μg/ml. Preferably, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1 μg/ml. 
     In one embodiment, the harvested APCs are contacted with a phagocytosable particle comprising a core and an HPV immunogen tightly associated to the core. The T-cell expansion method may comprise contacting APCs with 100 to 1×10 9  phagocytosable particles, for example 100 to 1×10 8 , for example 100 to 1×10 7  phagocytosable particles are used in a given expansion run, for example 1000 to 1×10 7  phagocytosable particles. For example, the ratio of phagocytosable particle to APC is in the range 1000:1 to 1:10. The ratio can be optimised depending on the size of the phagocytosable particle. For example, for a phagocytosable particle with a largest diameter of about 1 μm, the ratio may be in the range 50:1 to 2:1, for example 25:1 to 5:1, 15:1 to 7:1, or 10:1. 
     In some embodiments, the phagocytosable particle provided in step i) is a phagocytosable particle of the present invention and may have any of the properties and/or characteristics of the phagocytosable particles of the present invention described herein. 
     In one embodiment of the invention, the in vitro T-cell expansion method comprises adding low doses IL-2 to the HPV immunogen specific T-cell sample, for example greater than 1.25 U/ml (for example 1.25 U/ml, 2.5 U/ml, 5 U/ml, or 50 U/ml), preferably greater than 2.5 U/ml, 5 U/ml, or 50 U/ml. Antigen specific T-cell expansion occurs in the presence of the antigen-presenting cell when IL-2 is simultaneously present. The IL-2 promotes the differentiation of HPV immunogen specific T-cells into effector HPV immunogen specific T-cells and into memory HPV immunogen specific T-cells. Following expansion of HPV immunogen specific T-cells, the APCs may be removed from the expanded T-cell population, for example by magnetic separation. 
     In another embodiment of the invention, the method of expanding HPV immunogen specific T-cells comprises adding IL-2 and/or IL-7 and/or IL-15 to the HPV immunogen specific T-cell sample, for example a low dose of IL-2 to the HPV immunogen specific T-cell sample, for example greater than 1.25 U/ml (for example 1.25 U/ml, 2.5 U/ml, 5 U/ml, or 50 U/ml), preferably greater than 2.5 U/ml, 5 U/ml, or 50 U/ml of IL-2, with optional addition of IL-7 and/or IL-15. For example a low dose of IL-7 to the HPV immunogen specific T-cell sample, for example greater than 1.25 U/ml (for example 1.25 U/ml, 2.5 U/ml, 5 U/ml, or 50 U/ml), preferably greater than 2.5 U/ml, 5 U/ml, or 50 U/ml of IL-7; and/or for example, a low dose of IL-15 to the HPV immunogen specific T-cell sample, for example greater than 1.25 U/ml (for example 1.25 U/ml, 2.5 U/ml, 5 U/ml, or 50 U/ml), preferably greater than 2.5 U/ml, 5 U/ml, or 50 U/ml of IL-15. 
     In preferred embodiments of the invention, the method of activating and expanding HPV immunogen specific T-cells comprises a step of removing the APCs that have phagocytosed a phagocytosable particle of the invention from the HPV immunogen specific T-cells. In embodiments of the invention, wherein the phagocytosable particles of the invention comprises a magnetic core, the APCs are removed from the HPV immunogen specific T-cells by using magnetic separation. 
     Following contact of an HPV immunogen specific T-cell with an APC that has phagocytosed a phagocytosable particle of the invention, the degree of HPV immunogen specific T-cell activation may be determined, for example by comparing the degree of HPV immunogen specific T-cell activation to a relevant reference. Determining the degree of HPV immunogen specific T-cell activation may be performed using T-cell activation assays known in the art, for example an ELISpot, FluoroSpot, intracellular staining of cytokines with flow cytometry, FASCIA, proliferation assays (e.g. thymidine incorporation, CFSE or BrdU staining), specific TCR-detection with MHC-I or II tetramers, and ELISA- or Luminex analysis of secreted cytokinesELIS potassays. The method may comprise the step of comparing the degree of HPV immunogen specific T-cell activation to a relevant reference. Suitable references include, for example, a T-cell sample that does not comprise HPV immunogen specific T-cells, or an HPV immunogen specific T-cell sample that has not been contacted with an APC that has phagocytosed a phagocytosable particle. 
     T-Cell Populations 
     T-cell populations for use in the present invention generally comprises the T-cells in an appropriate physiologically acceptable medium. Such mediums are known in the art and include, for example, aqueous sterile injectable solutions (e.g. saline, such as PBS), cell culture mediums suitable for clinical use and autologous plasma, which may also contain anti-oxidants, buffering agent (e.g. sodium phosphate, potassium phosphate, TRIS and TEA), bacteriostats, and solutes which render the T-cell population dose isotonic with the blood of the intended recipient. 
     The population of T-cells for use in the present invention preferably comprises CD4+ T-cells and CD8+ T-cells, for example a mixture of CD4+ T-cells and CD8+ T-cells. For example, in one embodiment, the T-cell population may comprise predominantly CD4+ T-cells. Preferably, the T-cell population comprises predominantly HPV immunogen specific T-cells, for example, HPV immunogen specific CD4+ T-cells and CD8+ T-cells. 
     A T-cell population for use in the present invention may further comprise an adjuvant. The term “adjuvant” as used herein is to be understood as any substance that enhances an immune response towards an antigen. Examples of adjuvants for use in the present invention include dsRNA analogues, such as polyinosinic:polycytidylic acid, Incomplete Freund&#39;s Adjuvant, cytokines (for example, interleukins), CD40, keyhole limpet hemocyanin, Toll-like receptors, CpG oligodeoxynucleotides, saponins, aluminium salts (for example aluminium hydroxyphosphate sulphate, or aluminium hydroxide, hydrated (Al(OH) 3 , for example with 3-O-desacyl-4′-monophosphoryl lipid A (MPL) adsorbed on its surface), colloidal alum, and analogues of lipid A of lipopolysaccharide. 
     Treatments 
     The present invention provides a population of T-cells for use in the treatment or prophylaxis of HPV positive cancer in a subject. The present invention also provides methods of treating or preventing HPV positive cancer in a subject comprising the step of administering to the subject a population of T-cells of the invention. The present invention also provides a use of a population of T-cells of the invention for the manufacture of a medicament for the treatment or prevention of HPV positive cancer. 
     The treatments of the invention may be used to treat or prevent any form of HPV positive cancer, for example any HPV positive solid cancer, metastatic solid cancer or hematologic malignancy. The treatments of the invention are especially effective in the treatment of HPV positive cervical, vaginal, vulval, penile, anal, mouth, throat and head and neck cancers. The current invention is particularly effective for the treatment of penile cancers. 
     The treatments of the invention also find use in the treatment of patients having a refractory and/or relapsed HPV positive cancer. For example, the population of T-cells of the invention finds use in the treatment or prophylaxis of refractory and/or relapsed HPV positive cancers in patients that have previously been treated with a currently available treatment, such as single or repeat treatment cycles of a chemotherapeutic agent. 
     The treatments of the invention also find use in the treatment of subjects that have previously received a prophylactic HPV vaccine, for example a dose of a HPV vaccine such as Gardasil®, Gardasil 9° or Cervarix®. For example, the method of treatment can comprise a first step of injecting a subject with a HPV vaccine, followed by administering a dose of a population of HPV specific T-cells. The subject may also receive one or more further doses of HPV specific T-cells as required and described herein. The one or more doses of HPV specific T-cells can be administered to a subject immediately after a dose of HPV vaccine has been administered or one or more doses of HPV specific T-cells can be administered days, weeks, months or years after a dose of a HPV vaccine has been administered. 
     It is expected that the HPV specific T-cells of the invention will be effective in treating HPV positive cancers in subjects that have previously received a dose of a HPV vaccine that was ineffective at preventing the development of a HPV positive cancer in the subject. For example, the HPV cancer may have been ineffective at inducing immunity against a HPV immunogen in the subject, or the HPV vaccine may have induced immunity against a HPV immunogen from one strain of HPV, but the HPV positive cancer in the subject is caused by a different HPV strain. The present invention allows for the ex vivo expansion of T-cells that are specific to HPV immunogens that are known or suspected of being associated with a HPV positive cancer in a subject. The versatility of the method, phagocytosable particles and kits of the present invention enable the tailoring of the treatment to target the HPV positive cancer in the subject. 
     The treatments of the invention also find use in the treatment of subjects that are known or suspected of lacking immunity to the strain of HPV known or suspected of being associated with the cancer in the subject. The treatments of the invention also find use in subjects that are known or suspected of having reduced immunity against HPV or have an ineffective or compromised immune system. For the treatment of such subject, the method of the invention can comprise the ex vivo expansion of HPV specific T-cells that have been obtained from a compatible donor. In addition, or alternatively, the method can comprise obtaining T cells from the subject and expanding the HPV specific T-cells to a level that can be used a treat the HPV positive cancer in the subject. 
     Whilst a population of T-cells of the present invention may be use as the sole active ingredient for the treatment or prophylaxis of HPV positive cancer in a subject or in methods of treating or preventing HPV positive cancer in a subject comprising the step of administering to the subject a population of T-cells of the invention, it is also possible for a population of T-cells to be used in combination with one or more further therapeutic agents and/or in combination with radiation therapy. 
     Thus, the invention also provides a population of T-cells according to the invention together with a further therapeutic agent, for simultaneous, sequential or separate administration. The invention also provides a population of T-cells according to the invention together with a further therapeutic agent, for simultaneous, sequential or separate administration for use in the treatment or prophylaxis of HPV positive cancer in a subject, or for use in methods of treating or preventing HPV positive cancer in a subject comprising the step of administering to the subject a population of T-cells of the invention and the further therapeutic agent. 
     The further therapeutic agent may a therapeutic agent for use in the treatment or prophylaxis treatment or prophylaxis of HPV positive cancer. The further therapeutic agent may a therapeutic agent for use in the treatment or prophylaxis of cervical, vaginal, vulval, penile, anal, mouth, throat or head and neck cancers. 
     For example, the further therapeutic agent may be an immune checkpoint inhibitor, a chemotherapeutic agent or a phagocytosable particle comprising a core and a HPV immunogen of the present invention. 
     Examples of chemotherapeutic agent include alkylating agents, alkyl sulfonates, aziridines, ethylenimines and methylamelamines, acetogenins, a camptothecin, bryostatin, callystatin, CC-1065, cryptophycins, dolastatin, duocarmycin, eleutherobin, pancratistatin, a sarcodictyin, spongistatin, nitrogen mustards, antibiotics, enediyne antibiotics, dynemicin, bisphosphonates, esperamicin, chromoprotein enediyne antibiotic chromophores, aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, antimetabolites, erlotinib, vemurafenib, crizotinib, sorafenib, ibrutinib, enzalutamide, folic acid analogues, purine analogs, androgens, anti-adrenals, folic acid replenisher such as folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate, an epothilone, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidainine, maytansinoids, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid 2-ethylhydrazide, procarbazine, PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.), razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone; 2,2′,2″-trichlorotriethylamine, trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine), urethan, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside (“Ara-C”), cyclophosphamide, thiotepa, taxoids, chloranbucil, gemcitabine, 6-thioguanine, mercaptopurine, methotrexate, platinum analogs, vinblastine, platinum, etoposide (VP-16), ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, xeloda, ibandronate, irinotecan (Camptosar, CPT-11), topoisomerase inhibitor RFS 2000, difluorometlhylornithine, retinoids, capecitabine, combretastatin, leucovorin, oxaliplatin, inhibitors of PKC-alpha, Raf, H-Ras, EGFR and VEGF-A that reduce cell proliferation, and pharmaceutically acceptable salts, acids or derivatives thereof, and combinations thereof. 
     Examples of immune checkpoint inhibitors include an agent or antibody that inhibits one or more of CTLA4, PD-1, PD-L1, LAG-3, B7-H3, B7-H4, TIM3, VISTA and KIR. In one preferred embodiment, the further therapeutic agent is an immune checkpoint inhibitors, and in particular an immune checkpoint inhibitors that is an agent or antibody that inhibits one or more of CTLA4, PD-1, PD-L1, LAG-3, B7-H3, B7-H4, TIM3, VISTA and KIR. For example, the checkpoint inhibitor is an agent or antibody that inhibits CTLA-4, PD-1 or PD-L1. Examples of PD-1 inhibitors include cemiplimab, nivolumab and pembrolizumab. Examples of PD-L1 inhibitors include atezolizumab, avelumab and durvalumab. An example of a CTLA-4 inhibitor is ipilimumab. 
     Dosing and Dosage Regimens 
     A therapeutic dose of the population of T-cells expanded using the method of the present invention is a dose sufficient to treat or prevent cancer in a subject. For example, the therapeutic dose is sufficient to reduce the size of a HPV positive cancer and/or reduce the proliferation of HPV positive cancer cells in the subject. The population of T-cells may be administered to the subject intravenously, intraarterially, intrathecally or intraperitoneally. The precise dosage of a population of T-cells will vary with the characteristics of the T-cell population, for example, the number of T-cells, number of CD4+ T-cells, the number of CD8+ T-cells, and the number of HPV specific T-cells in the T-cell population expanded using the method of the present invention. Further factors, include for example, the dosing schedule, the age, size, sex and condition of the subject (typically mammal or human), the nature and severity of the condition, and other relevant medical and physical factors. Thus, a precise therapeutically effective amount can be readily determined by the clinician. An appropriate amount can be determined by routine experimentation from animal models and human clinical studies. For humans, an effective dose will be known or otherwise able to be determined by one of ordinary skill in the art. 
     In certain preferred embodiments, a subject is administered a therapeutic dose of HPV specific T-cells and is then administered at least one further (or “subsequent”) therapeutic dose of HPV specific T-cells of the invention, or an injectable composition comprising a therapeutic dose of HPV specific T-cells of the invention. Further (or “subsequent”) therapeutic doses of HPV specific T-cells may be administered daily, every second or third day, weekly, every second, third or fourth week, monthly, every second, third or fourth month, every 6 months, or every year. The number and frequency of further therapeutic dose(s) of HPV specific T-cells of the invention will depend on the subject, and the form and severity of the cancer to be treated. 
     In certain embodiments, a subject is administered a therapeutic dose of HPV specific T-cells and is then administered at least one further (or “subsequent”) therapeutic dose of HPV specific T-cells of the invention, or an injectable composition comprising a therapeutic dose of HPV specific T-cells of the invention. Further (or “subsequent”) therapeutic doses of phagocytosable particles may be administered daily, every second or third day, weekly, every second, third or fourth week, monthly, every second, third or fourth month, every 6 months, or every year. The number and frequency of further therapeutic dose(s) of HPV specific T-cells of the invention will depend on the subject, and the form and severity of the cancer to be treated. In one embodiment, the use of HPV specific T-cells for the treatment or prophylaxis of HPV positive cancer comprises administering one or more subsequent therapeutic doses of HPV specific T-cells to the subject, wherein the subject is one whom has previously been administered a therapeutic dose of HPV specific T-cells, or an injectable composition comprising a therapeutic dose of HPV specific T-cells of the invention. Each of the one or more subsequent therapeutic doses are a dose sufficient to reduce the size of a HPV positive cancer or reduce proliferation of a HPV positive cancer in a subject. 
     In another embodiment, the use of HPV specific T-cells for the treatment or prophylaxis of HPV positive cancer comprises administering one or more subsequent therapeutic doses of HPV specific T-cells to the subject, wherein the subject is one whom has previously been administered a therapeutic dose of HPV specific T-cells, or an injectable composition comprising a therapeutic dose of phagocytosable particles of the invention. Each of the one or more subsequent therapeutic doses are a dose sufficient to reduce the size of a HPV positive cancer or reduce proliferation of a HPV positive cancer in a subject. 
     In embodiments of the invention comprising administering one or more subsequent therapeutic doses of HPV specific T-cells to the subject, preferably 2, 3, 4, 5, 6, 7, 8, 9, 10 or n subsequent therapeutic doses of the HPV specific T-cells wherein “n” is any number of doses greater than 10 doses (for example 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 doses). Preferably, the number and frequency of subsequent therapeutic doses administered to the subject is sufficient to treat or prevent cancer in the subject. 
     In embodiments of the invention comprising administering one or more subsequent therapeutic doses of HPV specific T-cells to the subject, preferably, the one or more subsequent therapeutic doses are administered to the subject at intervals of days, weeks or months. For example, one or more subsequent therapeutic doses are administered to the subject every day, every second day, every third day, every fourth day, every fifth day or every sixth day. Alternatively, or additionally, one or more subsequent therapeutic doses are administered to the subject, for example, once every week, once every two weeks, once every three weeks or once every four weeks. Alternatively, or additionally, one or more subsequent therapeutic doses are administered to the subject, for example, once every month, once every two months, once every three months or once every 6 th  month. Alternatively, or additionally, one or more subsequent therapeutic doses are administered to the subject, for example, once every year. 
     In one embodiment of the invention, the one or more subsequent therapeutic doses are administered to the subject once every year, two times every year or three times every year. For example, the one or more subsequent therapeutic doses may be administered to the subject once every year, two times every year or three times every year for a period of 1 to 10 years, 10 to 20 years, 20 to 30 years, 30 to 40 years or 50 to 60 years. 
     It is expected that by administering one or more subsequent therapeutic doses to a subject over a long period of time (i.e. over one or more years), it is possible to boost the number of HPV specific memory T-cells that are present in the subject. It is expected that by boosting the number of HPV immunogen specific memory T cells in a subject maintains the HPV immunogen specific immunological memory in the subject, such that a HPV positive cancer is prevented from growing or returning. 
     In certain embodiments of the invention, a booster dose is administered to a subject whose cancer has been successfully treated (with one or more therapeutic doses as described herein) to prevent the HPV positive cancer returning. 
     A booster dose of HPV specific T-cells may independently have any of the properties and/or characteristics of a therapeutic dose of HPV specific T-cells as described herein. 
     In one embodiment of the invention, one or more booster doses are administered to the subject, for example, once every week, once every two weeks, once every three weeks or once every four weeks. Alternatively, or additionally, one or more booster doses are administered to the subject, for example, once every month, once every two months, once every three months or once every 6 th  month. Alternatively, or additionally, one or more booster doses are administered to the subject, for example, once every year. 
     In another embodiment of the invention, the one or more booster doses are administered to the subject once every year, two times every year or three times every year. For example, the one or more booster doses may be administered to the subject once every year, two times every year or three times every year for a period of 1 to 10 years, 10 to 20 years, 20 to 30 years, 30 to 40 years or 50 to 60 years. 
     It is expected that boosting the number of HPV immunogen specific memory T cells in a subject by administering one or more booster doses maintains the HPV immunogen specific immunological memory in the subject, such that the cancer is prevented from growing or returning. 
     Further aspects of the invention are defined in the following numbered clauses:
     § 1. A method for the expansion of HPV immunogen specific T-cells, comprising the steps of:
       i. providing a human papillomavirus (HPV) immunogen or a phagocytosable particle comprising a core and a HPV immunogen tightly associated to the core; wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein;   ii. providing APCs   iii. contacting the HPV immunogen or the phagocytosable particle comprising a core and a HPV immunogen with the APCs from step ii in vitro, and under conditions allowing phagocytosis of the HPV immunogen by the APCs;   iv. providing T-cells that have been harvested from the subject;   v. contacting the T-cells with the APCs from step iii) in vitro, and under conditions allowing specific activation of HPV immunogen specific T-cells.   
       § 2. A method as described in § 1 in which the T-cells have been harvested from a tumour draining lymph node in the subject.   § 3. A method as described in § 1 or § 2 in which the HPV immunogen includes one or more HPV proteins necessary for viral replication (e.g. E1 to E7) and HPV coat proteins (e.g. L1 and L2).   § 4. A method as described in § 3 in which the HPV immunogen includes one or more of HPV coat protein L1 derived from any one of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.   § 5. A method as described in § 4 in which the HPV immunogenic construct comprises HPV immunogens contained in a commercially available HPV vaccine (for example Gardasil®, Gardasil 9® or Cervarix®).   § 6. An expanded population of T-cells obtained by a method as claimed in any one of § 1 to § 5.   § 7. A population of T-cells as described in § 6 for use in the treatment of an HPV-mediated cancer.   § 8. A population of T-cells for use a described in § 7 wherein the HPV-mediated cancer is selected from cervical, vaginal, vulval, penile, anal, mouth, throat and head and neck cancers, for example penile cancer.   § 9. A phagocytosable particle comprising a core and a HPV immunogen tightly associated to the core; wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein.   

     The invention is further described by the following examples, which are not intended to limit the scope of the invention. 
     EXAMPLES 
     Example 1: General Protocol for Coupling HPV Immunogens or Model Peptides/Proteins to Magnetic Cores 
     Coupling of HPV immunogenic constructs or model peptides/proteins to a core: Dynabeads® MyOne™ Carboxylic Acid (ThermoFischer Scientific) were used (1 μm diameter spheres) as the core. Dynabeads® MyOne™ Carboxylic Acid particles are paramagnetic polystyrene particles comprising iron oxide and functionalised on the surface of the particle with free carboxylic acid groups. The coupling procedure may be carried out according to the manufacturer&#39;s protocol (Two-Step procedure using NHS (N-Hydroxysuccinimide) and EDC (ethyl carbodiimide)): 
     Step 1): The polystyrene particles are washed twice with MES-Buffer (25 mM MES (2-(N-morpholino)ethanesulfonic acid), pH 6). The carboxylic acid groups are then activated by adding 50 mg/ml NHS (N-Hydroxysuccinimide) and 50 mg/ml EDC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide) in MES-buffer to the polystyrene particles and incubated for 30 min at room temperature (RT). The polystyrene particles are collected with a magnet and the supernatant removed. The polystyrene particles are then washed twice with MES-buffer. 
     Step 2): The HPV immunogenic construct or model peptide/protein sample is diluted in MES-buffer to a concentration of 1 mg/ml, total 100 μg and added to the polystyrene particles and incubated for 1 h in room temperature. The polystyrene particles are collected with a magnet and the supernatant was removed and saved for peptide-concentration measurement. The non-reacted activated carboxylic acid groups are quenched with 50 mM Tris pH 7.4 for 15 min. The polystyrene particles are then washed with PBS pH 7.4 and then stored in −80° C. 
     A BCA (bicinchoninic acid) protein assay kit (Pierce BCA Protein Assay Kit, ThermoFisher Scientific) is used according to the manufacturer&#39;s protocol, to measure the amount of peptidic material coupled to the polystyrene particles and to measure the peptidic material concentration of the HPV immunogenic construct or model peptides/protein in a sample before coupling as well as the peptidic material concentration of the supernatant after coupling. 
     Example 2: Washes 
     Phagocytosable particles comprising a core (Dynabeads®) and a model protein (Ovalbumin or Cytomegalovirus protein pp65) attached to the core were prepared according to the protocol described in Example 1. After coupling the phagocytosable particles were washed with one of 3 different wash-buffers: 2M NaOH pH 14.3, 8 M Urea or 6 M Guanidine (Guanidine-HCl), all in sterile water at RT, or they were incubated in PBS at 95° C. The polystyrene particles were suspended in the buffer and shaken for 4 min, collected with a magnet and the supernatant removed. This was repeated 3 times. The heat treated polystyrene particles were put in PBS pH 7.4 and put in a heating block at 95° C. for 5 minutes, then collected with a magnet and the supernatant removed. This was repeated 3 times. The particles were then washed 3 times with sterile PBS to remove any remaining wash-buffer. 
     Four different washing conditions were tested: (a) High pH (2M NaOH pH 14.3), (b) Heat (95° C.) and sterilising/denaturing agents ((c) 8M Urea and (d) 6M guanidine hydrochloride). In every case, the model proteins associated with the polystyrene particles remained associated with the polystyrene particles. 
     Example 3a: Identification of Suitable Particle Size for Phagocytosable Particles Using Ovalbumin as Model Antigen 
     A cell proliferation assay measuring Thymidine incorporation was used to test the effect of phagocytosable particle size on antigen-specific T-cell activation. Splenocytes from ovalbumin (OVA) immunized mice were stimulated with OVA coupled polystyrene particles of different sizes to measure antigen specific proliferation. 
     Dynabeads® MyOne™ Carboxylic Acid particles with a diameter of 5.6 μm, 1 μm and 0.2 μm were coupled with OVA (OVA-particles) or bovine serum albumin (BSA-particles) according to the protocol in Example 1. 
     To test the effectiveness of the OVA-particles to stimulate antigen specific T-cell activation a proliferation assay (with  3 H thymidine incorporation) was used. Particle concentration in relation to cell concentration was 1:1 for the 5.6 μm particles, 10:1 for the 1 μm particles and 500:1 for the 0.2 μm particles. Total protein concentration during the incubation with the cells was calculated to 125 ng/ml, 160 ng/ml and 160 ng/ml for the 5.6 μm, 1 μm and 0.2 μm respectively. The proliferation assay was run as follows: 
     Proliferation assay with thymidine incorporation with splenocytes from ovalbumin sensitized mice. As stimuli, ovalbumin (SigmaAldrich) and BSA (SigmaAldrich) coupled to Dynabeads® MyOne™ Carboxylic Acid particles were used. Mice were immunized to ovalbumin via monthly injections of 100 μg ovalbumin (Sigma) adsorbed to aluminium hydroxide. Three months after the first injection the mice were killed and spleens harvested. Splenocytes were prepared by standard procedures, as described in Thunberg et al. 2009, Allergy 64:919. 
     The cells were incubated in cRPMI either with ovalbumin coupled beads or BSA coupled beads (10 beads per cell) for 5 days. All cells were incubated for 6 days in a humidified atmosphere with 6% CO 2  at 37° C. One μCu/well [ 3 H] thymidine was added to cell cultures for the final 18 h of incubation. Mean counts per minute (cpm) obtained from stimulated triplicates were divided by mean cpm values from un-stimulated cells and expressed as stimulation indices (SI). SI-values 2.0 are generally considered positive. 
     As seen in  FIG. 1 , cells incubated with OVA-particles with a diameter of 0.2 μm showed increase in proliferation with a mean SI of 4.1 (95% CI 2.4-5.8, P=0.007). The cells incubated with OVA-particles with a diameter of 1 μm showed increase in proliferation with a mean SI of 8.4 (95% CI 6.1-10.6, P&lt;0.005). The cells incubated with OVA-particles with a diameter of 5.6 μm failed to stimulate proliferation, mean SI 1.1 (95% CI 0.4-2.7, P=0.876). 
     These results show that antigen coupled to particles of different sizes can stimulate cell proliferation. The particles with a diameter of about 1 μm appear to be most efficient at stimulating cells, but particles with a size of 0.2 μm still work. The inventors predict that particles of sizes larger than 1 μm also work, although as the diameter comes close to 5.6 μm the particles completely fail to stimulate the cells. It is reasonable to assume that 1 μm is an optimal size, since it is similar to the size of bacteria. Our immune system has evolved to phagocytose and react to microorganisms/particles of this size. A normal antigen presenting cell has a size in the range 10-15 μm. 
     Example 3b: Comparison of Antigen Coupled Particles of Different Particle Sizes and their Effectiveness in Activating and Expanding T-Cells 
     (i) Preparation of Antigen Coupled Phagocytosable Particles: 
     Three kinds of paramagnetic polystyrene phagocytosable particles of different sizes were used:
         diameter of 1 μm (Dynabeads MyOne Carboxylic Acid, ThermoFisher),   diameter of 2.8 μm (Dynabeads M-270 Carboxylic acid, ThermoFisher) and   diameter of 4.5 μm (Dynabeads M-450 Epoxy, ThermoFisher).       

     The phagocytosable particles were coupled with the model virus antigen Cytomegalovirus (CMV) protein pp65 construct according to the manufacturer&#39;s instruction. The pp65 construct has as amino acid sequence according to SEQ ID NO. 15. The CMV pp65 construct contains five linked 22 to 23-amino acid pp65 peptides, an N-terminal histidine-tag, and N-terminal albumin-binding domain (ABD)-tag. The construct was recombinantly expressed using  E. coli  and purified using column chromatography. To remove endotoxin, the phagocytosable particles were washed five times with a 0.75M sodium hydroxide buffer and subsequently resuspended in sterile PBS. 
     
       
         
           
               
            
               
                 SEQ ID NO. 15: 
               
               
                 MGSSHHHHHHSSGSLAEAKVLANRELDKYGVSDYHKNLINNAKTVEGVK 
               
               
                   
               
               
                 DLQAQVVESAKKARISEATDGLSDFLKSQTPAEDTVKSIELAEAKVLAN 
               
               
                   
               
               
                 RELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALPGGSAETRLLQTG 
               
               
                   
               
               
                 IHVRVSQPSLILVGGSIIKPGKISHIMLDVAFTSHEHFGGSWPPWQAGI 
               
               
                   
               
               
                 LARNLVPMVATVQGGSRGPQYSEHPTFTSQYRIQGKLGGSQNLKYQEFF 
               
               
                   
               
               
                 WDANDIYRIFAE 
               
            
           
         
       
     
     (ii) Incubation of Antigen Coupled Phagocytosable Particles: 
     Peripheral blood mononuclear cells (PBMCs) from a CMV-sensitive healthy donor, isolated via standard ficoll-based density gradient centrifugation were cultured together with the phagocytosable particles coupled with the CMV construct (hereinafter referred to as “CMV-particles”) in a 48-well plate for 18 h at 37° C., 5% CO 2 , 500,000 cells/well at a concentration of 1,000,000 cells/ml. The concentration of CMV-particles were equalized based on total surface area (a surrogate marker for CMV amount as it is bound to the surface of the CMV-particles). This equalled to 10 CMV-particles/PBMC for the 1 μm sized particles, 1.4 CMV-particle/PBMC for the 2.8 μm sized particles and 0.5 CMV-particles/PBMC for the 4.5 μm sized particles, based on the number of total PMBCs in the sample. The results for each particle sized is shown below in Table 1. 
     
       
         
           
               
               
               
               
               
             
               
                   
                 TABLE 1 
               
               
                   
                   
               
               
                   
                   
                 Number  
                 Ratio of CMV- 
                 Number of  
               
               
                   
                 Particle  
                 of PBMCs  
                 particles  
                 CMV-particles  
               
               
                   
                 size 
                 in sample 
                 to PBMCs 
                 in sample 
               
               
                   
                   
               
             
            
               
                   
                   1 μm 
                 500,000 
                  10:1 
                 5,000,000 
               
               
                   
                 2.8 μm 
                 500 000 
                 1.4:1 
                 700 000 
               
               
                   
                 4.5 μm 
                 500 000 
                 0.5:1 
                 250 000 
               
               
                   
                   
               
            
           
         
       
     
     (iii) Assessment of Uptake: 
     After incubation, the number of phagocytosed CMV-particles were manually counted using a confocal microscope. Eight cells were counted to obtain mean and standard deviation values. In  FIG. 2A , there are shown images from the confocal microscope of representative cells with intracellular phagocytosed CMV-particles. Black dashed line indicates the outline of the cell. The white line shows the dimensions of the total intracellular CMV-particles. 
     This method was not applicable for the 1 μm CMV-particles as they were too small to accurately count. In order to assess the amount of 1 μm CMV-particles, the total volume of all phagocytosed CMV-particles were measured and the amount of individual CMV-particles were back-calculated based on the total volume, assuming a packing density of 60%. This method proved reasonably accurate for the 2.8 μm CMV-particles (manually counted 9.1 CMV-particles/cell vs estimated 11.9 CMV-particles/cell) and 4.5 μm CMV-particles (manually counted 3.1 CMV-particles/cell vs estimated 2.4 CMV-particles/cell) and can as such be assumed to accurately estimate the amount of 1 μm CMV-particles as well. 
     The uptake of CMV-particles in shown in  FIGS. 2B and 2C .  FIG. 2B  shows the number of CMV-particles taken up by each cell as assessed by manual counting (8 cells counted per bead-type). Using the manual counting method, it was found that the number of phagocytosed particles per cell for the 4.5 μm CMV-particles was of 3.1 (±1.1). For the 2.8 μm CMV-particles it was 9.1 (±2.2). It was not possible to count the number of 1 μm CMV-particles using this method. 
       FIG. 2C  shows the number of CMV-particles taken up by each cell as assessed by the volume calculation (3 cells measured per bead-type) (*p&lt;0.05 **p&lt;0.01 ***p&lt;0.001, calculated using Students T-test). Using the volume calculation method, it was found that the number of phagocytosed particles per cell for the 4.5 μm CMV-particles was of 2.4 (±1.1). For the 2.8 μm CMV-particles it was 11.9 (±3.2). For the 1 μm CMV-particles it was 203.7 (±21.9). 
     Based on the number of CMV-particles taken up by each cell as assessed by the volume calculation method, the total phagocytized surface area, and by extension the total amount of CMV, was calculated. The surface area that was taken up was calculated as 639.6 (±68.9) μm 2  for the 1 μm CMV-particles, 293.1 (±79.3) μm 2  for the 2.8 μm CMV-particles and 150.7 (±67.0) μm 2  for the 4.5 μm CMV-particles. These data are shown in Table 2 below. 
     
       
         
           
               
               
               
               
             
               
                 TABLE 2 
               
               
                   
               
               
                   
                 CMV-particles uptake 
                 CMV-particles uptake per cell 
                 Surface area taken  
               
               
                 Particle size 
                 per cell (counted) 
                 (calculated from volume) 
                 up per cell 
               
               
                   
               
             
            
               
                   1 μm 
                 — 
                 203.7 (±21.9) 
                 639.6 (±68.9) μm 2   
               
               
                 2.8 μm 
                 9.1 (±2.2) 
                 11.9 (±3.2) 
                 293.1 (±79.3) μm 2   
               
               
                 4.5 μm 
                 3.1 (±1.1) 
                  2.4 (±1.1) 
                 150.7 (±67.0) μm 2   
               
               
                   
               
            
           
         
       
     
     (iv) Assessment of T-Cell Stimulation 
     The ability of the antigen coupled particles to stimulate T-cells and hence promote their expansion was assessed by measuring the release of IFNγ, IL-22 and IL-17A from PBMCs using a FluoroSpot assay (Mabtech, Sweden). PBMCs (250,000/well) from CMV-sensitive healthy donors (n=2) were stimulated with the CMV-particles in triplicates. The concentration of antigen coupled particles were as previously described equalized based on total surface area: 10×1 μm CMV-particles/cell, 1.4×2.8 μm CMV-particles/PBMC and 0.5×4.5 μm CMV-particles/cell. The number of PBMCs per well of the FluoroSpot assay is shown below (Table 3) for each particle size, together with the estimated number of monocytes per well (based on an estimated 20% monocyte content of a PBMC sample). 
     
       
         
           
               
               
               
             
               
                 TABLE 3 
               
               
                   
               
               
                   
                 Number of  
                 Number of  
               
               
                 particle size 
                 PBMCs per well 
                 monocytes per well 
               
               
                   
               
             
            
               
                   1 μm 
                 250,000 
                 50,000 
               
               
                 2.8 μm 
                 250,000 
                 50,000 
               
               
                 4.5 μm 
                 250,000 
                 50,000 
               
               
                   
               
            
           
         
       
     
     The PBMCs were incubated for 44 h at 37° C., 5% CO 2 . The plates were developed according to the manufacturer&#39;s instructions and read in an automated FluoroSpot reader. The data reported for the FluoroSpot is spot-numbers when the cells are stimulated with CMV-particles above the spot-numbers when not stimulated with CMV-particles. 
     The level of IFNγ-production, as assessed in the FluoroSpot assay, is shown in  FIG. 3A . It is seen that there is little difference between the CMV-particles. 
     The level of IL-22 and IL-17 production, as assessed in the FluoroSpot assay, is shown in  FIGS. 3B and 3C . It is seen that the 1 μm CMV-particles caused a significantly higher IL-22 and IL-17 production in one individual than the larger CMV-particles, with a similar trend seen for the other individual in regards to IL-22. 
     The level of dual-cytokine production, as assessed in the FluoroSpot assay, is shown in  FIGS. 3D and 3E . It is seen that the 1 μm CMV-particles caused a significantly higher dual-cytokine release (IFNγ+IL-17 and IL-22γ+IL-17) for one healthy donor when stimulated with the 1 μm CMV-particles than with the larger CMV-particles. 
     The cytokine release in these experiments serves as a proxy for T-cell expansion. In general, IFNγ is produced by CD4+ T-cells (Th1 subclass) and CD8+ T-cells. IL-17 and IL-22 are mainly produced by pro-inflammatory Th17 CD4+ T-cells. Such cells are pro-inflammatory have been shown to assist in tumour eradication. The data suggest that the 1 μm phagocytosable particles activate and cause expansion of Th1 CD4+ T-cells and CD8+ T-cells to the same degree as the other beads, with the added benefit of also activating and causing expansion of additional pro-inflammatory Th17 CD4+ T-cells and the less distinct but still pro-inflammatory double cytokine producing T-cells. 
     Example 4: Study of HPV in a Cohort of Penile Cancer Patients 
     Patients 
     11 patients with invasive penile cancer, 50-84 years old, from Sodersjukhuset, Stockholm and Norrlands Universitetssjukhus, Umea, Sweden, (2013-2015) undergoing radical surgery and regional lymph node dissection, were included (Table 4). Preoperative staging; cT1-2N0-1M0. The study was approved by the regional ethical committee and informed consent was obtained from all participants (EPN- 2013/835-32). 
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 4 
               
               
                   
               
               
                   
                   
                 Clinical Tumour 
                 No of excised 
                 No of metastatic 
               
               
                 Patient No 
                 Age 
                 staging 
                 lymph nodes 
                 lymph nodes 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 1 
                 84 
                 T2N0M0 
                 4 
                 0 
               
               
                 2 
                 72 
                 T1N0M0 
                 3 
                 0 
               
               
                 3 
                 72 
                 T2N0M0 
                 4 
                 0 
               
               
                 4 
                 78 
                 T1N0M0 
                 2 
                 0 
               
               
                 5 
                 66 
                 T1N0M0 
                 5 
                 0 
               
               
                 6 
                 50 
                 T2N0M0 
                 4 
                 0 
               
               
                 7 
                 80 
                 T2N0M0 
                 7 
                 0 
               
               
                 8 
                 77 
                 T1N0M0 
                 4 
                 0 
               
               
                 9 
                 78 
                 T2N1M0 
                 8 
                 1 
               
               
                 10 
                 78 
                 T1N0M0 
                 4 
                 2 
               
               
                 11 
                 70 
                 T2N0M0 
                 4 
                 0 
               
               
                   
               
            
           
         
       
     
     Preparation of Specimens 
     One piece of primary tumour was dissected at surgery, and further used for PCR analyses and antigen source preparation. Lymph nodes (LNs) were identified and removed, and one half of LNs respectively underwent routine histopathology and immunological evaluation. 
     Preparation of Single Cells 
     Venous blood, LNs, and tumour specimens were immediately harvested. Peripheral blood mononuclear cells (PBMC) were purified by ficoll-hypaque (Pharmacia, Amersham). Single cell suspensions from tissue specimens were obtained by gentle pressure using a loose-fit glass-homogenizer. Cells were washed twice and resuspended in AIM V® (Life technologies). 
     Flow Cytometry (FACS) 
     PBMC, LNs and tumour cell suspensions at 0.5×10 6  cells/sample were washed in PBS containing 2% FCS and 0.05% NaN 3  (FACS-buffer). For investigating subtypes of lymphocytes and their functions, staining was performed with fluorophore conjugated antibodies: Blue Live/Dead stain, anti-CD4 Pacific-Blue, anti-CD8 APC, anti-CD19 APC-Cy7 and anti-CD56 PE (Becton Dickinson). Cells were investigated with LSRFORTESSA (Becton Dickinson) and analysed using the FACS DIVA software (Becton Dickinson). 
     Activation of T Cells 
     Tumour samples were homogenized using an Ultra-Turrax homogenizer in 5 volumes (w/v) of RPMI, followed by 5 minutes denaturation at 98° C. Activation of single cell suspensions of PBMC, lymph node cells and T-cells were tested at 0.5 million cells/tube using tumour homogenate, Gardasil® (0.1-1.0 μg/ml) or Pokeweed mitogen (PWM) (5 mg/ml) (Sigma-Aldrich) in medium. Activation was measured by blast transformation (day 7) and cell surface markers according to FASCIA, using the methods as described in Svahn et al. J. Immunol. Methods, 2003, 277(1-2):17-25. 
     PCR Assay 
     Tumour samples were stored in RNA-later (Ambion, Austin, Tex., USA) and extracted for DNA by DNAeasy Blood and Tissue kit (Qiagen). Primers (see Camargo et al., J. Virol. Methods 2011, 178(1-2), 68-74, and Sahiner et al., Diagn. Microbiol. Infect. Dis. 2014, 80(1), 43-9) were used for detection of the L1-region of HPV Type 16 (HPV16) and HPV Type 18 (HPV18). HPV18 DNA extracted from HeLa cells and HPV16 DNA (Advanced Biotechnologies) were used as positive controls. PCR assay was performed by Bio-Rad T100 following a standard PCR protocol. 
     Example 4:1: HPV Classification of Tumours 
     DNA was extracted from 5 available tumours (for patients 7 to 11) and analysed by PCR using HPV primers for the L1 gene from the most common disease-causing strains: HPV 16 and 18. In samples from 2 of the 5 tested patients HPV virus was detected (patients 8 and 9). The observed frequency of 40% was comparable with the reported frequency in the literature of 46.3% (Tornesello M L, et al., Int. J. Cancer, 2008, 122:132-137). 
     Example 4:2: Immunophenotyping of LNs 
     Single cell suspensions obtained from tumour, lymph nodes and peripheral blood were analysed by FACS. The proportion of different lymphocyte population in LNs varied between the patients and they are shown in Table 5. 
     
       
         
           
               
               
               
               
               
               
               
             
               
                 TABLE 5 
               
               
                   
               
               
                 Patient 
                 Average % 
                 Average % 
                 Average 
                 Average % 
                 Average % 
                   
               
               
                 No. 
                 CD4 +   
                 CD8 +   
                 CD4/CD8 
                 CD19 +   
                 CD56 +   
                 HPV 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 1 
                 43.9 
                 7.87 
                 6.11 
                 38 
                 5.2 
                 ND 
               
               
                 2 
                 21.40 
                 4.97 
                 4.46 
                 52.67 
                 0.50 
                 ND 
               
               
                 3 
                 49.9 
                 20 
                 2.57 
                 41.25 
                 25.4 
                 ND 
               
               
                 4 
                 68.4 
                 13.95 
                 4.94 
                 43.35 
                 1.5 
                 ND 
               
               
                 5 
                 69.05 
                 5 
                 13.81 
                 15.05 
                 0.6 
                 ND 
               
               
                 6 
                 59.57 
                 7.37 
                 8.53 
                 21.77 
                 0.83 
                 ND 
               
               
                 7 
                 81.30 
                 3.60 
                 19.92 
                 6.67 
                 0.43 
                 No 
               
               
                 8 
                 74 
                 11.7 
                 5.60 
                 12.4 
                 2.4 
                 Yes 
               
               
                 9 
                 38.9 
                 2.55 
                 15.39 
                 33.5 
                 1.25 
                 Yes 
               
               
                 10 
                 29.33 
                 39.43 
                 0.75 
                 20.57 
                 12.00 
                 No 
               
               
                 11 
                 66.67 
                 5.57 
                 11.97 
                 18.83 
                 0.80 
                 No 
               
               
                   
               
               
                 (ND = Not determined) 
               
            
           
         
       
     
     It is seen that the average fraction of CD4+ T-cells in LNs was between 21-81% and for CD8+ T-cells was 2.5-39%. 
     Next, the CD4/CD8 ratios between LN and peripheral blood were compared. There was a significant difference (p=0.0009) in the CD4+/CD8+ ratios between PBMCs and LNs: the CD4+/CD8+ ratio in PBMCs was 2.5 compared to 10 in LNs. This demonstrates expansion of CD4+ T-cells in LNs. 
     The lymphocyte populations were compared and a significant correlation between CD8+ T-cells and CD56+ expressing lymphocytes was found (Spearman r=0.67, p&lt;0.0001), ( FIG. 4A ). Furthermore, an inverse correlation between the fraction of CD19+ B cells and CD4+ T-cells was also found (Spearman r=−0.71, p&lt;0.0001) ( FIG. 4B ). In addition, an inverse correlation between the fraction of CD19+ B cells and the CD4+/CD8+ ratio (Spearman r=−0.61, p&lt;0.0001) ( FIG. 4C ) was found. It was noted that patients who died from penile cancer within two years from diagnosis (patients 1, 6, 10) displayed low CD4+/CD8+ ratio and/or low CD19+ cells. 
     The CD4+/CD8+ ratios in LNs according to respective HPV-status was analysed. The inventors found a significantly decreased (p&lt;0.05) CD4+/CD8+ ratio in LNs derived from HPV positive patients. These results suggest that there was a relative increase in HPV recognizing CD8+ T-cells in HPV patients ( FIG. 5 ). 
     Example 4:3: Tumour and Reactivity in Draining Lymph Nodes 
     T-cell responses were tested against a tumour lysis extract. In 13 available LNs from six patients, immune responses towards tumour extract were investigated by FASCIA, as described in Marits et al. Clin. Immunol., 2014, 153(2):332-342. 
     CD4+ T-cell blast transformation was observed as a response in 6/13 LNs (46%) to tumour extract. Correspondingly, CD8+ T-cell blast responses were seen in 7/13 (54%) LNs ( FIG. 6 ). In total an immune response (either CD4+ or CD8+) was observed in 9 out of 13 tested LNs by FASCIA using autologous tumour extract as antigen (69%). Thus, 5 out of 6 tested patients (83%) demonstrated a T-cell recognition of a tumour associated antigen present in autologous tumour extract. 
     Example 4:4: HPV Reactivity in Draining Lymph Nodes 
     Both Gardasil® and tumour extract stimulation was carried out with LN cells from the two HPV positive patients (patient No 8 and 9). When tumour extract was used as antigen for stimulation, a small T-cell response (for both CD4+ T-cells and CD8+ T-cells) in the FASCIA was noted with PBMC cells (see  FIG. 7  in which the data for a PBMC sample from patient No 8 are shown). However, a strong response (for both CD4+ and CD8+ T-cells) was found in PBMCs and in LN cells in the HPV positive patients when Gardasil® was used as the antigen for stimulation (see  FIG. 7  in which the data for samples from PBMCs and two LNs from patient No 8 are shown). 
     Both HPV-positive patients (patients 8 and 9) responded to Gardasil® and to tumour extract. Only absent or very weak responses towards Gardasil® were noted in HPV-negative patients, demonstrating that L1 protein responses were restricted to HPV-positive patients. 
     In a dose response assay, Gardasil® was added to the cell culture at levels from 0.1-1 μg/ml and blast transformation was evaluated on day 7. The LN-derived lymphocytes from HPV-positive patient 9 responded in a dose dependent manner against Gardasil® ( FIG. 8A ), where 1 μg/ml of Gardasil® resulted in a 5-fold increase in response compared to 0.3 μg/ml of added antigen. 
     When the cell surface expression of the T-cell activation marker HLA-DR (Human Leukocyte Antigen—DR isotype) was investigated, a 10-fold increase from unstimulated to Gardasil® stimulated group was seen, substantiating that there was Gardasil® dependent T-cell activation ( FIG. 8B ). 
     SUMMARY 
     The present inventors have observed tumour antigen specific T-cell responses in LNs from patients with penile cancer for the first time. Moreover, HPV-positive patients demonstrated T-cell responses against the L1 components of the Gardasil® vaccine. 
     The distribution of lymphocytes varied, but a significant increase in the CD4+/CD8+ ratios in LNs compared to PBMCs was detected ( FIG. 4B ) indicating expansion of CD4+ T-cells in LNs. 
     The present inventors also found that HPV infected penile cancer patients displayed a significant decrease of the CD4+/CD8+ ratio in LNs, indicating activation and expansion of HPV recognizing CD8+ T-cells ( FIG. 5 ). 
     Although, CD56+ is known as a Natural Killer (NK) lymphocyte cell marker, CD56 is also expressed on activated cytotoxic CD8+ T-cells (Pittet et al., J. Immunol. 2000, 1, 164(3), 1148-1152), indicating that LNs contain an increased number of activated CD8+ T-cells, further demonstrating their state of activation ( FIG. 4A ). Additionally, an activation of CD4+ T-cells in LNs responding to the HPV-L1 proteins from HPV 16 and/or 18 present in Gardasil® was observed, further supporting the notion of a HPV specific immune response. 
     The FASCIA assay used the addition of tumour homogenate or L1 proteins from HPV 16 and/or 18 present in Gardasil®, and the length of the peptides or the exogenously provided homogenate promotes presentation in the MHC class II pocket and hence stimulation of CD4+ T-cells. The activation of CD8+ T-cells against Gardasil® was poor in PBMC cultures, but they responded significantly in LN cultures ( FIG. 7 ). This suggests that cross presentation is present in LN cultures where specialized dendritic cells may have the capacity to load MHC class I molecule for CD8+ T cell activation (Bonaccorsi et al., Crit. Rev. Immunol., 2015, 35(5), 349-364). 
     The increased T-cell proliferation to Gardasil® compared to tumour extract suggests that Gardasil® contains higher concentrations of pure antigens compared to autologous tumour extracts. The demonstration of a dose-dependent response towards L1 proteins shows that Gardasil® is a useful source of antigen for expansion of HPV-specific T-cells in HPV-positive penile cancer patients. The expanded cells find use in adoptive T-cell therapy. 
     Example 5: Ex-Vivo T-Cell Expansion Using Particles Coupled to the Model Virus Antigen CMV pp65 
     (i) Preparation of the CMV Pp65 Construct Coupled Phagocytosable Particles (Herein Referred to as “CMV-Particles”): 
     The phagocytosable particles (Sera-Mag Speed Beads Carboxylate-Modified magnetic particles, GE Healthcare) were coupled with the CMV pp65 construct (SEQ ID NO. 15). To remove endotoxin, the phagocytosable particles were washed five times with a 2M sodium hydroxide buffer and subsequently resuspended in sterile PBS. 
     (ii) Incubation of CMV-Particles with PBMCs: 
     Peripheral blood mononuclear cells (PBMCs) from a CMV positive donor, isolated via standard ficoll-based density gradient centrifugation were cultured together with the CMV-particles. PBMCs were seeded in cell culture media at approximately 2 to 5 million cells/ml. On Day 0, the CMV-particles were added to the culture at a ratio of particles to antigen-presenting cells of between 1:1 and 1:20. Cells were cultured for 20 days and the cell density was maintained at approximately 2 to 5 million cells/ml throughout the entire culture procedure. At appropriate intervals during the culture procedure, the culture media was changed and the cell number and the cell viability assessed. Cell viability was assessed using a Trypan blue exclusion assay (Saveen Werner). Cell number and viable cells were counted using a LUNA™ Automated Cell Counter following the manufacture&#39;s guidelines. After 20 day, the cell number in the culture had expanded approximately 13 times ( FIG. 9A ), and approximately 80% of the cells in the culture were viable ( FIG. 9B ). Notably, the percentage of viable cells remained substantially constant (at around 80%) throughout the entire culturing procedure. 
     (iv) Immunophenotyping of PMBCs Following Addition of CMV-Particles 
     The viability and phenotype of the cultured PBMCs were assessed using FACS analysis. PBMCs that did not undergo stimulation with CMV particles were also analysed as a control (referred to as PBMC baseline). FACS was performed using a LSRFORTESSA (Becton Dickinson) and data were analysed using the FACS DIVA software (Becton Dickinson). PBMC samples were removed from the culture and washed in PBS containing 2% FCS and 0.05% Na N 3  (FACS-buffer). For investigating subtypes of lymphocytes and their functions, staining was performed with the following fluorophore conjugated antibodies: Blue Live/Dead stain, anti-CD4 Pacific-Blue, anti-CD8 APC, and anti-CD3 (Becton Dickinson). The FACS gating used in the analysis is shown in  FIG. 10A . 
     The FACS analysis shows that after 19 days of culturing the PBMC cells with the CMV-particles, 98% of the cells in the culture were CD3+ cells, of which 49% were CD8+ cells and 33% were CD4 cells ( FIGS. 10B , C and D). 
     (iv) Assessment of T-Cell Stimulation 
     The ability of the CMV-particles to stimulate T-cells and hence promote T-cell expansion was also assessed by measuring the release of IFNγ from the expanded T-cells using a FluoroSpot assay (Mabtech, Sweden). Cells (“Expanded PMBCs”) were removed from the culture 19 days after addition of the CMV-particles and re-exposed to the same type of CMV-particles as used in the expansion protocol, or exposed to uncoupled beads (phagocytosable particles without an antigen attached), media, or albumin-binding domain (ABD). IFNγ release from these cells was then analysed using the FluoroSpot assay, which was used in accordance with the manufacture&#39;s guidelines. As a negative control, a PBMC sample that had not undergone ex-vivo expansion using the CMV-particles (“PBMC Baseline”) was exposed to CMV-particles, uncoupled beads, media only or albumin-binding domain (ABD). Wells containing cells that released high levels of IFN-γ displayed a higher level of fluorescence. To show that the cell culture contained T-cells, samples of the Expanded PMBCs and PBMC Baseline cells were also exposed to a fluorescently labelled anti-CD3 antibody (shown as “a-CD3” in  FIG. 11A ). 
     Results 
     As shown in  FIGS. 11A and 11B , the expanded T-cells (“Expanded PBMCs”) showed notably higher levels of IFNγ release compared to the cells exposed to uncoupled beads, media only or albumin-binding domain (ABD). Only a low level of IFNγ release was observed for the PBMC Baseline cells incubated with the CMV-particles prior to analysis in the FluoroSpot assay. This data indicates that the CMV-particles enriched the PBMCs taken from the CMV-positive donor with CMV-specific T-cells. 
     Example 6: Phagocytosable Particle Toxicity and Biodistribution Study 
     Materials and Method 
     Particles used in study: Sera-Mag SpeedBead Carboxylate-Modified Magnetic Particles (Hydrophilic). These particles are supplied by GE Healthcare Life Sciences (Particle Lot/Batch Number GE: 16807675, concentration: 2.3% solids (g/100 g) (corresponding to 10 mg Fe/mL) in Dulbecco&#39;s phosphate buffered saline, pH 7.1). The particles are stored prior to use at 2-8° C. 
     Animal details: Rats, Wistar. On arrival to the study location, the rats have an approximate weight of 250 g. Rats are acclimatised for a minimum of 5 days prior to the start of the study. The rats are kept in individually ventilated cages (type IVC 4) at +22° C.±3° C., a humidity of 50%±20% and with 12-hour light/12-hour dark cycles. Food and water are available ad libitum. There are three rats per cage. 
     Study 1): 
     Five female Wistar rats are used in the pilot study. Rat #1 is subjected to intravenous (IV) injection with the maximum feasible concentration of particle (concentration equivalent to 50 mg/kg iron at 5 mL/kg), after which the rat is placed in a computed tomography (CT) camera for acquisition of an image. Intravenous injection is performed as slowly as possible. If a toxic response is evident, particles are delivered to the remaining rats by slow infusion over a period of 20 minute (max 20 mL/kg). The particle concentration delivered to the rats is titrated until a maximum tolerated dose is identified. A rat that has not received a dose of particles is used as a negative control and for acquisition of a background CT scan. 
     Following IV injection/infusion of the particles, the rats are anaesthetised with isoflurane and ophthalmic ointment is placed on the eyes to prevent dehydration. Rats are then placed on the heated bed of a CT instrument, where inhalation anaesthesia is maintained. Vital parameters (pulse and respiration) are monitored during the course of the experiment using a respiration sensor and rectal thermometer. Rats are inserted into the CT camera, where a picture is acquired over the course of about 20 minutes. Health status following IV injection of particles is documented to assess possible toxic reactions, and a whole-body CT image is used to assess particle visibility and to determine the location of particles following injection. Following acquisition of a CT image, the rats are euthanised. 
     Study 2): 
     A further study is performed using twelve rats to identify the rate of particle elimination. All rats receive an IV injection of the particles at a dose identified in the pilot study. Immediately after administration of the particles, the rats are placed in a CT camera. The rats are thereafter monitored in the CT camera at 24 h, 3 days, 7 days, 14 days and 1 month after administration. At each time point, two rats are euthanised for excision of organs for histopathological analysis. The rats are monitored for changes in health status and body weights 24 h, 3 days and 7 days after administered and once weekly thereafter. 
     Example 7: Exemplification of Phagocytosable Particle Sterilisation Protocol Using  Bacillus subtilis    
     This experiment was performed under sterile conditions in a laminar air flow (LAF) safety cabinet. Phagocytosable particles comprising a core (Sera-Mag SpeedBeads Carboxylate-Modified magnetic particles, GE Healthcare) attached to a neoantigen construct were washed four times with high concentration alkaline solution (2M to 5M NaOH). After the first wash, the phagocytosable particles were transferred to a new sterile tube, the supernatant was removed, and a second volume of alkaline solution was added. Phagocytosable particles were sonicated for 10 minutes in a sonication bath, and then incubated for 30 minutes with end-over-end rotation in the same alkali solution. This process was repeated a further two times, followed by four washes with sterile Dulbecco-modifies PBS. 
     Effectiveness of the NaOH treatment protocol was evaluated by spiking phagocytosable particles (Sera-Mag SpeedBeads Carboxylate-Modified magnetic particles, without attached neoantigen) with a high load (&gt;1.2 CFU) of  Bacillus subtilis  subsp.  spizizenii  (ATCC® 6633™ Epower 106 CFU), followed by the above described NaOH treatment protocol. After NaOH treatment, both full bead suspension and supernatant from non-treated (positive control) vs 5M or 2M NaOH treated samples were plated on nutrient agar in the absence of antibiotics, and incubated at 37° C. overnight (&gt;16 hours). 
     Results 
     Both 5M and 2M NaOH treatment effectively abolished bacterial growth, whereas colonies of  Bacillus subtilis  subsp.  spizizenii  were abundantly growing in the absence of washes. In conclusion, both the 2M and 5 M NaOH treatments were highly effective at removing an artificially high bioburden load from the phagocytosable particles.